Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4787 companies, A–Z).
Cincinnati Financial posted investor presentation slides on November 9, 2026 for use from November 10, 2026. The slides show third-quarter 2026 EPS of $2.96 versus $7.11 in 3Q25, while non-GAAP operating income was $443 million compared with $449 million, and the combined ratio rose to 90.9%. The company said its year-to-date value creation ratio of 5.8% was below its 10% to 13% long-term target.
3Q26 EPS of $2.96 per share versus $7.11 per share in 3Q25
Non-GAAP operating income of $443 million versus $449 million in 3Q25
Combined ratio of 90.9%, 2.7 percentage points higher than 3Q25, including 7.0 points from higher catastrophe losses
YTD 9-30-26 value creation ratio of 5.8%, below the 10% to 13% target; P&C net written premiums grew 4%
Somnigroup released an updated investor presentation on November 9, 2026, alongside its third-quarter 2026 results. Third-quarter net sales rose 10.8% to $2,351 million, and adjusted EPS rose to $1.04 from $0.95, but GAAP net income fell 7.8% to $164 million and GAAP EPS fell to $0.74 from $0.83. The company's 2026 outlook calls for adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion.
Q3 2026 net sales were $2,351 million, up from $2,123 million in Q3 2025
Q3 2026 GAAP EPS was $0.74, down from $0.83; adjusted EPS was $1.04, up from $0.95
Q3 2026 adjusted EBITDA was $448 million, up from $419 million
2026 outlook: adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Fervo Energy reported third-quarter 2026 results, with net income of $11.7 million driven largely by a $29.9 million tax benefit and an $11.8 million non-cash swap gain, while operating loss widened to $43.7 million from $13.7 million a year earlier. The company lowered its expected second-half 2026 capital spending to $700 million to $750 million from $850 million to $900 million, and said Cape Google 400 commercial operation dates are unchanged, which matters for shareholders weighing construction costs and timing.
Q3 2026 net income of $11.7 million, versus a net loss of $15.8 million in Q3 2025; the release cites $15.4 million of interest income and two non-recurring items
Q3 2026 operating loss of $43.7 million; general and administrative expense rose to $39.4 million from $27.4 million in Q2 2026
Second-half 2026 capital expenditure outlook cut to $700 million to $750 million from $850 million to $900 million, with no change to expected commercial operation dates
Signed a 15-year take-or-pay power purchase agreement with Google for 396 megawatts, with first power expected mid-2028
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
Year-to-date bookings: approximately $18.76 million as of November 6, 2026
Revenue converted from bookings: $1.388 million through September 30, 2026
Contracted demand is nearly 14 times full-year 2025 bookings
Roughly half of 2026 contracts are from new customers
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Safe Harbor reported third-quarter 2026 revenue of $1.95 million, up 6.5%, while swinging to a net loss of approximately $979,000 from net income a year earlier that included a $3.34 million debt extinguishment gain. The company also disclosed a nonbinding term sheet with Opifex Media Inc. under which Opifex security holders would own about 85% of the combined company, and the company's common share count rose sharply after Series B conversions, which shareholders should weigh against these results.
Q3 2026 revenue was $1.95 million, up from $1.83 million; net loss was approximately $979,000, or $0.95 per share, versus net income of approximately $180,000 in Q3 2025.
Nonbinding term sheet with Opifex Media Inc. signed October 23, 2026; Opifex holders would own approximately 85% of the combined company's fully diluted shares, with the Safe Harbor share adjustable from 12.5% to 17.5%.
Series B conversion price reset to $0.1210 on October 22, 2026; common shares outstanding rose from 1,028,702 on September 30 to 132,248,520 on November 6, 2026.
Nasdaq granted an additional period through April 19, 2027 to regain compliance with the $1 minimum bid price; cash was $4.4 million at September 30, 2026, and the filing includes a going concern disclosure.
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
OPAL Fuels reported third quarter 2026 revenue of $79.5 million, down 5% from a year earlier, while Adjusted EBITDA rose 32% to $26.7 million and net income was $1.7 million versus a $1.9 million loss. The company now expects 2026 RNG production to be modestly below its guidance range and expects full-year Adjusted EBITDA at the lower end of its guidance range, which it maintained, so shareholders face weaker production expectations even as profit measures improved.
Q3 2026 revenue was $79.5 million, down 5% from $83.4 million in Q3 2025; nine-month revenue was $236.3 million, down 5%.
Q3 2026 Adjusted EBITDA was $26.7 million, up from $20.2 million; net income was $1.7 million versus a $1.9 million loss; basic and diluted EPS was $(0.03), unchanged year over year.
Company now expects 2026 RNG production to be modestly below its guidance range; 2026 Adjusted EBITDA guidance was maintained, with results expected at the lower end of the range.
Three new RNG projects with about 2.0 million MMBtu of annual design capacity are expected to begin commercial operations over 2027.
Quanterix reported third-quarter 2026 revenue of $35.0 million, up 6.3% from the second quarter but down from $40.2 million a year earlier, and a net loss of $21.6 million, compared with $33.5 million a year earlier. The company narrowed its 2026 total revenue outlook to $142-146 million, which gives shareholders a clearer range for the full year.
Q3 2026 revenue of $35.0 million, compared with $40.2 million in Q3 2025 and up 6.3% from Q2 2026.
Net loss of $21.6 million, or $0.46 per share, compared with a net loss of $33.5 million, or $0.73 per share, a year earlier.
2026 total revenue outlook narrowed to $142-146 million; adjusted gross margin expectation of 48-50% unchanged; year-end cash expected at about $70 million with no debt.
Cash, cash equivalents, marketable securities and restricted cash totaled $80.7 million at September 30, 2026.
Uniti Group reported third quarter 2026 revenue of $848.1 million, up from $722.6 million a year earlier, but posted a net loss of $244.5 million, compared with net income of $1,608.9 million in the prior-year quarter that included a $1,685.4 million gain on settlement of preexisting relationships. Adjusted EBITDA was $289.3 million, down from $327.8 million, and the company raised its full-year 2026 revenue outlook to $3.665 billion to $3.695 billion while projecting a net loss of $590 million to $620 million.
Third quarter revenue of $848.1 million, up from $722.6 million in the same quarter of 2025
Net loss of $244.5 million, versus net income of $1,608.9 million in the prior-year quarter, which included a $1,685.4 million settlement gain
Adjusted EBITDA of $289.3 million, down from $327.8 million a year earlier
2026 outlook: revenue of $3.665 billion to $3.695 billion, net loss of $590 million to $620 million, and Adjusted EBITDA of $1.46 billion to $1.49 billion
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
RB Global reported third-quarter 2026 results with revenue up 17% year over year to $1.3 billion and net income up 47% to $140.2 million, helped by a one-time $18.2 million excise tax refund. The company raised its full-year 2026 GTV growth outlook to 14% to 15% from 9% to 11% and narrowed its adjusted EBITDA range to $1,525 million to $1,545 million from $1,495 million to $1,545 million, while also declaring a $0.33 quarterly dividend.
Diluted EPS was $0.70, up 63%; diluted adjusted EPS was $1.03, up 11%
Full-year 2026 GTV growth outlook raised to 14% to 15% from 9% to 11%; adjusted EBITDA low end raised to $1,525 million
Repurchased about 3.9 million shares for $350.0 million in the quarter; $500.0 million remained under the NCIB as of September 30, 2026
Quarterly dividend of $0.33 per share payable December 17, 2026, to holders of record November 25, 2026
Turning Point Brands reported third-quarter 2026 results, with net sales up 27.0% to $151.1 million, driven by growth in its Modern Oral products. Net income attributable to the company fell 81.4% to $3.9 million, and diluted EPS was $0.19 versus $1.13 a year earlier, as sales and marketing spending increased. The company reaffirmed its full-year 2026 guidance, which it had last updated on September 21, 2026.
Net sales rose 27.0% to $151.1 million; Modern Oral net sales rose 102.9% to $74.4 million.
Net income attributable to Turning Point Brands fell 81.4% to $3.9 million; diluted EPS was $0.19 versus $1.13.
Adjusted EBITDA fell 41.3% to $18.4 million, including increased sales and marketing investments.
Full-year 2026 guidance reaffirmed: Modern Oral net sales of $260-$270 million and Adjusted EBITDA of $70-$80 million.
WhiteHorse Finance reported third quarter 2026 results for the period ended September 30, 2026, with net investment income of $4.4 million, or $0.207 per share, down from $4.7 million in the prior quarter. Net asset value per share rose to $11.82 from $11.77, and the board declared a $0.25 per share distribution payable January 6, 2027, while the adviser agreed to lower its incentive fee rate to 17.50%.
Net investment income was $4,439 thousand, or $0.207 per share, down 5.2% from $4,681 thousand in Q2 2026; core net investment income rose 2.7% to $4,806 thousand, or $0.224 per share
Net asset value per share increased to $11.82 from $11.77; net realized losses were $3,631 thousand
Quarterly distribution of $0.25 per share payable January 6, 2027 to holders of record as of December 21, 2026; a special distribution of $0.17 per share is payable December 10, 2026
Adviser voluntarily reduced the incentive fee rate from 20.00% to 17.50% for the quarter ending December 31, 2026
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
CECO Environmental reported third-quarter 2026 revenue of $404.4 million, up 105% from a year earlier, following its June 1, 2026 acquisition of Thermon. The company swung to a GAAP net loss of $2.0 million, though non-GAAP net income rose to $34.3 million. It raised its full-year 2026 orders and free cash flow conversion outlook, kept its revenue and Adjusted EBITDA outlook unchanged, and introduced a 2027 outlook.
Q3 2026 revenue was $404.4 million, up 105%; GAAP net loss was $2.0 million versus net income of $1.5 million a year earlier.
Non-GAAP diluted EPS was $0.60 versus $0.26; Adjusted EBITDA was $70.1 million, up 202%.
2026 orders outlook raised to exceed $2.5 billion from at least $2.0 billion; free cash flow conversion raised to about 100% of Adjusted EBITDA from at least 55%.
2026 revenue ($1.300 billion to $1.375 billion) and Adjusted EBITDA ($200 million to $225 million) outlooks were maintained; 2027 revenue outlook is $2.1 billion to $2.3 billion.
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
RadNet reported third-quarter 2026 revenue of $638.3 million, up 22.1%, and Adjusted EBITDA of $105.0 million, up 23.8%, both described as records. GAAP net income attributable to common stockholders fell to $4.2 million, or $0.05 per diluted share, from $5.4 million, or $0.07, a year earlier. The company raised its 2026 Imaging Center guidance for revenue, Adjusted EBITDA and free cash flow, and raised Digital Health Adjusted EBITDA guidance.
Q3 2026 revenue was $638.3 million, up from $522.9 million; Adjusted EBITDA was $105.0 million, up from $84.9 million.
GAAP net income attributable to RadNet common stockholders was $4.2 million ($0.05 per diluted share) versus $5.4 million ($0.07) in Q3 2025; adjusted diluted EPS was $0.30 versus $0.24.
Imaging Center guidance raised to $2,385-$2,435 million revenue, $350-$363 million Adjusted EBITDA and $120-$130 million free cash flow.
Digital Health Adjusted EBITDA fell 11.8% to $3.0 million in Q3; cash was $750.6 million at September 30, 2026, and the pending ONRAD acquisition was referenced.
Air Industries Group reported results for the three and nine months ended September 30, 2026, in a press release furnished under Item 2.02. Third-quarter net sales rose 41.1% and the company swung to net income from a loss a year earlier, though results include merger-related costs tied to its pending merger with Tenax Aerospace Acquisition, LLC.
Q3 2026 net sales were $14.6 million, up from $10.3 million in Q3 2025; net income was $946,000 versus a net loss of $44,000.
Nine-month net sales were $38.2 million, up 8.7%, and the net loss narrowed to $902,000 from $1.5 million.
Q3 operating costs included $539,000 of stock compensation and merger-related expenses, with $503,000 of merger-related expense.
The company cited October 2026 net sales of about $5.6 million and firm customer orders in backlog of $95.4 million.
Popular, Inc. filed an 8-K updating its third-quarter 2026 results after a commercial borrower in the quick service restaurant industry substantially ceased operations and filed for Chapter 11 bankruptcy following the earnings release. The company recognized an additional $38 million provision for credit losses, lowering quarterly net income to $242.4 million from $266.3 million and diluted EPS to $3.83 from $4.21, and it raised its 2026 net charge-off guidance to 90 bps to 95 bps from 80 bps to 90 bps.
Q3 2026 net income of $242.4 million, down $23.9 million from the $266.3 million in the original earnings release.
Diluted EPS of $3.83 versus $4.21 as originally issued; up from $3.14 in the same quarter of 2025.
The company expects an additional fourth-quarter 2026 charge-off on the same relationship.
2026 net charge-off guidance raised to 90 bps to 95 bps from 80 bps to 90 bps; Common Equity Tier 1 ratio of 16.01%, down 5 bps.
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% from a year earlier, and nine-month net product revenue of $143.6 million, up 92%. Net loss attributable to common stockholders rose to $184.6 million for the quarter from $67.3 million, mainly due to non-cash fair value changes in a related-party convertible note, warrant and derivative liabilities after a higher common stock price, along with higher interest expense and operating costs.
Q3 2026 net product revenue was $48.7 million, up 53% year-over-year; nine-month net product revenue was $143.6 million, up 92%.
Q3 2026 net loss attributable to common stockholders was $184.6 million, versus $67.3 million in Q3 2025; basic loss per share was $0.17 versus $0.07.
Nine-month net loss attributable to common stockholders was $1.0 billion, versus $289.5 million a year earlier.
Cash, cash equivalents and marketable securities totaled $334.3 million as of September 30, 2026.
AN2 Therapeutics reported third-quarter 2026 results, with net loss narrowing to $8.0 million from $9.4 million a year earlier as research and development and general and administrative expenses declined. The company reported $80.2 million in cash, cash equivalents and investments as of September 30, 2026, and projects that this will fund operations into 2029 under its current plan.
Q3 2026 net loss was $8.0 million ($0.17 per share), versus $9.4 million ($0.31 per share) in Q3 2025.
R&D expenses were $5.7 million, down from $7.0 million, and G&A expenses were $2.9 million, down from $3.0 million.
Cash, cash equivalents and investments totaled $80.2 million at September 30, 2026, which the company projects will sustain operations into 2029.
Global Phase 2 study of oral epetraborole in polycythemia vera is cleared in all planned jurisdictions, with enrollment expected to begin by year-end 2026.
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, up from $3.3 million a year earlier, with TONMYA contributing $15.0 million. The net loss available to common stockholders widened to $53.3 million from $32.0 million, as research and development and selling, general and administrative expenses rose sharply. The company said its cash resources will meet its requirements into the early third quarter of 2027, a timeline shareholders will weigh against the larger losses.
Net product revenue was $17.2 million versus $3.3 million a year earlier; TONMYA net revenue was $15.0 million, up 37% from the second quarter.
Net loss available to common stockholders was $53.3 million, or $2.89 per share, compared with $32.0 million, or $3.59 per share, a year earlier.
R&D expenses were $25.8 million and SG&A expenses were $45.6 million, compared with $9.3 million and $25.7 million a year earlier.
Cash and cash equivalents were about $163 million as of September 30, 2026; the company expects them to fund operations into the early third quarter of 2027.
Roivant reported results for the quarter ended September 30, 2026, its first quarter with sales of LISRAYA (brepocitinib), which launched in August 2026. Revenue rose to $35.1 million from $1.6 million a year earlier, but the net loss attributable to Roivant widened to $191.6 million, or $0.27 per share, from $113.5 million, or $0.17, partly due to $95.9 million of distributions tied to Moderna settlement proceeds.
LISRAYA generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026.
Net loss attributable to Roivant was $191.6 million, or $0.27 per share, versus $113.5 million, or $0.17 per share, a year earlier.
Net loss included $95.9 million of distributions on Genevant equity awards tied to Moderna settlement proceeds.
Cash, cash equivalents and marketable securities were $4.2 billion as of September 30, 2026.
Powerfleet reported fiscal second-quarter 2027 revenue of $115.7 million, up 4% year over year, but its net loss attributable to common stockholders widened to $6.9 million from $4.3 million. The company said it has agreed in principle to a device financing facility with Rand Merchant Bank, subject to definitive documentation, and affirmed its fiscal 2027 revenue and adjusted EBITDA guidance.
Revenue rose to $115.7 million from $111.7 million, while gross margin fell to 53% from 56%.
Profit from operations was $1.4 million, compared with $4.2 million a year earlier, per the statement of operations.
Agreed in principle to a device financing facility with Rand Merchant Bank; terms remain subject to definitive documentation.
Fiscal 2027 guidance affirmed: revenue of $468 million to $473 million and adjusted EBITDA of $111 million to $114 million.
Tango Therapeutics reported a third quarter 2026 net loss of $68.4 million, or $0.39 per share, compared with net income of $15.9 million, or $0.13 per diluted share, in the same quarter of 2025. Collaboration revenue fell to $0 from $53.8 million after the Gilead collaboration concluded research activities in August 2025, while research and development and general and administrative spending both rose.
Collaboration revenue was $0 in Q3 2026, versus $53.8 million in Q3 2025.
R&D expenses rose to $48.9 million from $30.8 million; G&A expenses rose to $29.2 million from $8.9 million.
Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
Tango intends to initiate a Phase 3 study of vopimetostat plus daraxonrasib in front-line pancreatic cancer in the first half of 2027.
Superior Group reported third quarter 2026 net sales of $146.0 million, up 5% from $138.5 million a year earlier, but net income fell to $2.6 million, or $0.17 per diluted share, from $2.7 million, or $0.18. The company narrowed its full-year 2026 net sales and adjusted EPS forecasts by raising the low end of each range, which signals somewhat firmer expectations for shareholders.
Q3 2026 net sales of $146.0 million, up 5% from $138.5 million in Q3 2025
Net income of $2.6 million, or $0.17 per diluted share, versus $0.18 a year earlier
Adjusted EBITDA of $6.7 million, down from $7.5 million; CEO cited incremental charges tied to the Healthcare Apparel strategic shift
2026 net sales outlook narrowed to $578.0 million to $585.0 million; adjusted EPS outlook narrowed to $0.60 to $0.66
Ocular Therapeutix reported third quarter 2026 results with total net revenue of $12.9 million, down from $14.5 million a year earlier, and a net loss of $94.8 million, or $(0.42) per share, versus a net loss of $69.4 million, or $(0.38) per share, in the prior-year quarter. Research and development expenses rose to $74.8 million from $52.4 million, and the company said it had $530.6 million in cash as of September 30, 2026, with runway expected into 2028.
Net revenue was $12.9 million for Q3 2026, compared with $14.5 million for Q3 2025.
Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier.
R&D expenses were $74.8 million versus $52.4 million, reflecting faster HELIOS-3 and SOL-X enrollment and higher headcount.
Cash and cash equivalents were $530.6 million as of September 30, 2026; the company expects this to support operations into 2028.
Hain Celestial reported fiscal first quarter 2027 results for the quarter ended September 30, 2026, with net sales down 29% to $260 million and a net loss of $11 million, narrowed from $21 million a year earlier. The company said final regulatory approvals were received in early November 2026 for the sale of its International business to AURELIUS, but a condition requiring a credit agreement amendment by October 12, 2026 was not satisfied, and discussions on a path forward continue.
Net sales were $260 million, down 29% year over year; organic net sales fell 7%.
Net loss was $11 million, or $0.12 per diluted share, versus $21 million, or $0.23, a year earlier; adjusted EBITDA was $18 million versus $20 million.
Final required regulatory approvals for the International sale to AURELIUS were received in early November 2026.
The credit agreement amendment condition due October 12, 2026 was not satisfied; total debt was $586 million at quarter end.
Ceva reported third quarter 2026 results, with total revenue of $29.1 million, up 2% from a year earlier, and a GAAP net loss of $2.3 million, down from $2.5 million. The GAAP operating loss widened to $3.5 million from $2.1 million, and gross margin fell, so profitability trends are mixed.
Total revenue was $29.1 million, up 2% year over year; royalty revenue was $12.7 million, up 18% sequentially.
GAAP diluted loss per share was $0.08, compared with $0.10 a year earlier; non-GAAP diluted earnings per share was $0.13, versus $0.11.
GAAP operating loss was $3.5 million, compared with $2.1 million, and GAAP gross margin was 85%, compared with 88%.
The CFO said a significant multi-year connectivity agreement expected in the third quarter was signed in early fourth quarter 2026.
AMG reported third-quarter 2026 results. Consolidated revenue rose to $595.2 million from $528.0 million, but diluted EPS fell to $6.64 from $6.87, and the prior-year quarter included affiliate transaction gains. Non-GAAP Economic EPS rose to $9.50 from $6.10, and the company repurchased $400 million of stock and declared a $0.01 per share dividend.
Diluted EPS was $6.64 versus $6.87 a year earlier; net income (controlling interest) was $173.3 million versus $212.4 million.
Economic EPS (non-GAAP) was $9.50 versus $6.10; Adjusted EBITDA (controlling interest) was $353.7 million versus $250.9 million.
Consolidated revenue was $595.2 million versus $528.0 million; AUM was $973.9 billion at September 30, 2026, with net client cash flows of $20.7 billion in the quarter.
Quarterly dividend of $0.01 per share is payable December 3, 2026 to holders of record on November 19, 2026.
Foghorn Therapeutics reported third-quarter 2026 net income of $58.2 million, compared with a net loss of $15.8 million a year earlier, on collaboration revenue of $83.5 million, up from $8.2 million. Most of the revenue increase came from a $74.1 million cumulative catch-up adjustment tied to updated estimated future costs for ending the FHD-909 and SMARCA2 selective degrader programs, so the result is largely a one-time accounting effect.
Diluted earnings per share were $0.80, compared with a loss of $0.25 per share in the prior-year quarter.
Research and development expenses fell to $18.8 million from $20.0 million, and general and administrative expenses fell to $5.8 million from $6.7 million.
A new $2.3 million restructuring cost line appeared in the quarter.
Cash, cash equivalents and marketable securities were $156.2 million at September 30, 2026, with cash runway into the second half of 2029.
Select Water Solutions reported third-quarter 2026 revenue of $412 million, up 28% from a year earlier, and net income of $22.9 million, compared with $2.3 million in the third quarter of 2025. The company guided fourth-quarter Adjusted EBITDA to $95 million to $100 million and raised its 2026 net capital expenditure outlook to about $300 million to $310 million, while reporting that it closed the Pilot Water acquisition after quarter end.
Revenue was $412 million, up $90 million or 28% year over year; Adjusted EBITDA was $93.5 million, up from $59.5 million a year earlier.
Fourth-quarter 2026 Adjusted EBITDA is expected to be $95 million to $100 million; 2026 net capital expenditures are now expected to be about $300 million to $310 million.
After quarter end, the company issued $900 million of 7.625% senior notes due November 1, 2034, and entered a new $500 million revolving credit facility that was undrawn as of November 9, 2026.
Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.
Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.
Village Farms reported third-quarter 2026 consolidated net sales of $66.9 million, nearly unchanged from $66.7 million a year earlier, with record cannabis sales of $55.0 million offset by lower cannabis gross margin of 48% versus 55%. Net income attributable to shareholders was $10.0 million, or $0.08 per share, compared with $10.2 million a year earlier, and adjusted EBITDA from continuing operations fell to $18.2 million from $20.7 million.
Consolidated net sales were $66.9 million for Q3 2026, versus $66.7 million in Q3 2025.
Cannabis net sales rose 3% to $55.0 million, while cannabis gross margin was 48%, down from 55%, which the company attributed mainly to a softer Canadian spot trim market.
Net income attributable to shareholders was $10.0 million, or $0.08 per share, versus $10.2 million in the prior-year quarter.
The company closed the quarter with $80 million in cash and a net cash position of $41 million.
Editas Medicine reported third quarter 2026 results, with a net loss attributable to common stockholders of $23.4 million, or $0.15 per share, down from $25.1 million, or $0.28 per share, a year earlier. Collaboration revenue rose to $10.4 million from $7.5 million, driven mainly by partner milestone revenue, while research and development and general and administrative expenses also increased. The company said its cash runway extends into the second half of 2028.
Net loss attributable to common stockholders was $23.4 million, or $0.15 per share, for the three months ended September 30, 2026, versus $25.1 million, or $0.28 per share, a year earlier.
Collaboration and other research and development revenues increased to $10.4 million from $7.5 million, mainly from milestones achieved by a strategic partner.
Cash, cash equivalents, and marketable securities were $190.2 million as of September 30, 2026, up from $146.6 million at December 31, 2025, and are expected to fund operations into the second half of 2028.
Editas received Australian ethics and regulatory approval to start the Phase 1/2 Strive study of EDIT-401, with initial safety and tolerability data expected in the first quarter of 2027.
Praxis Precision Medicines reported a third-quarter 2026 net loss of $94.2 million, up from $73.9 million a year earlier, while its loss per share narrowed to $3.23 from $3.36 on a larger share count. The company had $1.3 billion in cash and investments at September 30, 2026, which it says funds operations into 2028, and it has two FDA applications under review with target action dates of December 27, 2026 and January 29, 2027.
Net loss was $94.2 million for Q3 2026 versus $73.9 million for Q3 2025; loss per share was $3.23 versus $3.36.
General and administrative expenses rose to $42.7 million from $12.6 million, mainly on $17.2 million in higher personnel costs and $9.4 million in higher professional expenses.
Cash, cash equivalents and marketable securities were $1.3 billion at September 30, 2026, which the company says funds operations into 2028.
FDA target action dates are December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide; Investor Day is November 12, 2026.
Virtus Investment Partners reported third-quarter 2026 results for the period ended September 30, 2026, with GAAP revenue of $197.6 million, down 9% from a year earlier, and diluted EPS of $3.26 versus $4.65. Assets under management fell 16% year over year to $141.4 billion, with net outflows of $6.1 billion, which weighs on future fee revenue for shareholders.
GAAP diluted EPS was $3.26 versus $4.65 a year earlier and $6.68 in the prior quarter; adjusted diluted EPS was $5.86 versus $7.35 a year earlier.
Revenue was $197.6 million, down 9% from $216.4 million a year earlier and down 2% from $201.4 million in the prior quarter.
Ending assets under management were $141.4 billion, down from $169.3 billion a year earlier, with net outflows of $6.1 billion.
The company repurchased 64,666 shares for $10.0 million and raised its quarterly dividend 2% to $2.45 per share.
GCM Grosvenor reported third quarter 2026 results, with GAAP net income attributable to the company up 17% to $12.3 million and fee-related earnings up 15% to $53.9 million from a year earlier. The company also approved a $0.12 per share dividend payable December 15, 2026, to holders of record on December 1, 2026.
Q3 2026 GAAP revenue was $145.6 million, up 8% year over year; adjusted net income rose 20% to $44.6 million.
Diluted earnings per share of Class A common stock were $0.17, up 6% from $0.16 a year earlier.
Fee-paying assets under management reached $78 billion, up 11%, and the company raised $2.7 billion of new capital in the quarter.
$54.1 million remained under the share repurchase authorization as of September 30, 2026.
ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.
Cash and marketable securities were $141.9 million as of September 30, 2026.
The updated investor presentation says current cash is expected to support operating plans into mid-2027.
The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
The filing does not include revenue, net income or loss, or earnings per share.
Ispire Technology reported results for the quarter ended September 30, 2026. Revenue fell 9.3% from a year earlier, mainly on lower European sales, and the net loss widened to $6.4 million from $3.3 million, largely due to $4.8 million of credit loss expense. Compared with the prior quarter, revenue rose 3.2% and the net loss narrowed, and adjusted EBITDA turned positive at $136,000.
Revenue was $27.5 million, down from $30.4 million a year earlier, and up 3.2% from $26.7 million in the prior quarter.
Net loss was $6.4 million, or $(0.11) per share, versus $3.3 million, or $(0.06) per share, a year earlier.
Credit loss expense rose to $4.8 million from $1.8 million; adjusted EBITDA was $136,000 versus $0.6 million a year earlier.
Gross margin was 16.2%, compared with 17.0% a year earlier and 6.3% in the prior quarter.
Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $(0.21) per share, up from $1.9 million, or $(0.07) per share, a year earlier. The company said its $10.4 million in cash as of September 30, 2026 is expected to fund operations into the third quarter of 2027, which matters to shareholders given the higher loss and the need for further capital.
Q3 2026 net loss was $6.2 million, or $(0.21) per basic and diluted share, versus $1.9 million, or $(0.07), in Q3 2025
Net loss from change in fair value of derivative liability instrument was $3.3 million in the quarter, compared with none in the prior-year period
Cash and cash equivalents were $10.4 million at September 30, 2026, with operations expected to be funded into the third quarter of 2027
Via Transportation reported third-quarter 2026 revenue of $143.5 million, up 31% from a year earlier, and a net loss of $18.8 million, down from $36.9 million. The company also issued fourth-quarter and full-year 2026 revenue outlook ranges, with full-year platform revenue expected at $556.7 million to $558.4 million.
Q3 2026 revenue was $143.5 million, up 31% from $109.7 million in Q3 2025.
Net loss per share was $0.23, compared with $1.49 a year earlier; Adjusted Net Loss per share was $0.00 versus $0.37.
Adjusted EBITDA was a loss of $3.2 million, compared with a loss of $8.7 million in Q3 2025.
Q4 2026 platform revenue is expected at $150.0 million to $151.7 million, and FY 2026 at $556.7 million to $558.4 million.
Constellation Energy reported third quarter 2026 results, with GAAP net income of $1.84 billion, or $5.19 per share, up from $930 million, or $2.97 per share, a year earlier. The company raised the midpoint of its full-year adjusted operating earnings guidance and narrowed the range to $12.50 to $12.80 per share, which signals stronger expected profit for shareholders.
Q3 2026 adjusted operating earnings were $5.06 per share, compared with $3.04 per share in Q3 2025
Q3 2026 operating revenues were $9.55 billion, compared with $6.57 billion in Q3 2025
Full-year 2026 adjusted operating earnings guidance narrowed to $12.50 to $12.80 per share, with the midpoint raised
Agreed to acquire the Rhode Island State Energy Center from Shell Energy North America for $715 million
KKR reported third quarter 2026 results, with GAAP net income attributable to common stockholders of $1.1 billion, up from $860 million a year earlier, and diluted EPS of $1.19 versus $0.90. Total revenues fell to $4.56 billion from $5.53 billion, largely in the Insurance segment, while the company said fee related earnings, total operating earnings and adjusted net income per share were all records on a quarterly and trailing twelve-month basis.
GAAP net income to common stockholders was $1.1 billion in Q3 2026 versus $860 million in Q3 2025; diluted EPS was $1.19 versus $0.90.
Total revenues were $4.56 billion versus $5.53 billion a year earlier; Insurance revenues were $2.80 billion versus $3.78 billion.
Fee Related Earnings were $1.3 billion, up 27% year over year; adjusted net income was $1.6 billion ($1.78 per adjusted share), up 29%.
The board approved a $500 million increase to the share repurchase program on November 6, after $567 million of repurchases from June 30 through November 4.
Target Hospitality reported third quarter 2026 revenue of $129.1 million, up 30% from a year earlier, and Adjusted EBITDA of $34.2 million, up 59%. The company also posted a net loss of $9.2 million, or $0.09 per share, compared with a loss of $0.8 million, or $0.01 per share, a year earlier. It reaffirmed its full-year 2026 outlook, which covers revenue of $435 to $445 million and Adjusted EBITDA of $105 to $115 million.
Q3 2026 revenue was $129.1 million, up from $99.4 million in Q3 2025.
Workforce Hospitality Solutions revenue rose to $79.5 million from $36.8 million, with 6,222 average utilized beds.
Full-year 2026 outlook was reaffirmed: revenue of $435 to $445 million and Adjusted EBITDA of $105 to $115 million.
Ferguson reported net sales of $9.0 billion for the quarter ended September 30, 2026, up 9.5%, with reported diluted EPS of $3.08, down 4.9%, and adjusted EPS of $3.43, up 7.9%. The company raised its 2026 net sales growth guidance to about 7% from mid-single digits, citing year-to-date performance and the FloWorks acquisition, while buybacks are paused and net debt to adjusted EBITDA rose to 1.7x from 1.0x.
Q3 net sales $9.0 billion, up 9.5%, including 7.0% organic growth
Reported diluted EPS $3.08, down 4.9%; adjusted diluted EPS $3.43, up 7.9%
2026 net sales growth guidance raised to about 7% from mid-single digits; adjusted operating margin guidance 9.6%-9.8%
Quarterly dividend of $0.89 payable January 8, 2027; share repurchases paused after FloWorks, with buybacks expected to resume as leverage falls
loanDepot reported a third-quarter 2026 net loss of $29 million, up from $7 million in the prior quarter, on total revenue of $307 million, down 9% from $337 million. Origination volume fell 12% sequentially to $7.05 billion, though it rose 8% from a year earlier, and the company said higher interest rates and a difficult housing market weighed on results.
Net loss of $29 million versus $7 million in Q2 2026; diluted loss per share of $0.08 versus $0.02
Adjusted EBITDA of $17 million, down from $20 million in Q2 2026
Sold $10 billion of Agency mortgage servicing rights; agreed to sell another $9 billion of Government MSRs, which closed in October
Repurchased $87 million of senior notes at an average 88% of par; company is pursuing financing alternatives to refinance or extend debt
NRG reported third-quarter 2026 GAAP net income of $561 million, up from $152 million a year earlier, and Adjusted EBITDA of $2,013 million, up from $1,205 million. The company reaffirmed its 2026 guidance, initiated 2027 guidance, and agreed to sell six gas-fired generation assets totaling 4.9 GW to LS Power for $4 billion in cash, with closing expected in the second quarter of 2027.
Q3 2026 GAAP EPS (basic) was $2.59 versus $0.70 a year earlier; Adjusted EPS was $4.68 versus $2.78.
2026 guidance reaffirmed, including Adjusted EPS of $7.90 to $9.90 and Adjusted EBITDA of $5,325 million to $5,825 million.
2027 guidance initiated, with Adjusted EPS of $8.05 to $10.05; the 2027 plan includes $1 billion of share repurchases and an 8% dividend increase to $2.05 per share.
The 4.9 GW sale to LS Power is for $4 billion in cash, subject to closing adjustments and approvals including HSR, FERC and the NYSPSC.
CNH reported third-quarter 2026 revenues of $4.35 billion, roughly flat year over year, and reported net income of $35 million, down from $67 million, after a $156 million non-cash deferred tax valuation allowance charge in Brazil. Adjusted net income rose to $205 million, helped by $109 million in pre-tax IEEPA tariff refunds, and the company raised its 2026 adjusted EPS and free cash flow guidance, which matters to shareholders because the results mix a weaker reported profit with improved adjusted and outlook figures.
Reported net income was $35 million, or $0.02 per diluted share, versus $67 million, or $0.06, in Q3 2025.
Adjusted net income was $205 million versus $109 million; adjusted diluted EPS was $0.16 versus $0.08.
Consolidated revenues were $4.35 billion, down 1% from $4.40 billion a year earlier.
2026 adjusted diluted EPS guidance was raised to $0.44 to $0.48 from $0.41 to $0.46, and Industrial Activities free cash flow guidance to $300 million to $450 million from $200 million to $400 million.
Somnigroup reported third-quarter 2026 net sales up 10.8% to $2.35 billion, including $372.6 million from Leggett & Platt after its August 26, 2026 acquisition. GAAP diluted EPS fell 10.8% to $0.74, while adjusted EPS rose 9.5% to $1.04, and the company revised its full-year 2026 adjusted EPS guidance to $2.85 to $2.95. The company also declared a quarterly dividend of $0.17 per share.
Q3 net sales rose 10.8% to $2,350.8 million; GAAP net income fell 7.8% to $163.5 million
Full-year 2026 adjusted EPS guidance revised to a range of $2.85 to $2.95, about 7% above 2025 adjusted EPS at the midpoint
Quarterly dividend of $0.17 per share, payable December 7, 2026, to holders of record on November 23, 2026
Abeona reported third-quarter 2026 results, with net ZEVASKYN revenue of $13.5 million, up 18% from $11.4 million in the second quarter, and a net loss of $4.8 million, or $0.08 per share, compared with $20.2 million, or $0.35 per share, in the prior quarter. The company also announced the $20 million stock-based acquisition of ABO-801 and a $30 million private placement, which it said will fund pipeline development and ZEVASKYN commercialization.
Net ZEVASKYN revenue was $13.5 million in Q3 2026, up 18% from $11.4 million in Q2 2026; one treatment's revenue was not recognized because its batch did not meet the identity assay release criterion.
Net loss was $4.8 million ($0.08 per share) in Q3 2026, versus $20.2 million ($0.35 per share) in Q2 2026.
Cash, cash equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30, 2026; the figure excludes the $30 million private placement completed after quarter end.
Abeona issued $20 million of common stock to Ellodi Pharmaceuticals for the ABO-801 asset, with no upfront cash, plus up to $60 million in additional milestone payments and royalties.
Sable Offshore reported third quarter 2026 revenue of $154.4 million, up 13% from the prior quarter, with average net sales volumes up 29% to about 27 thousand barrels of oil per day. The company said its sole downstream crude purchaser halted purchases in early October 2026, which it describes as creating near-term working capital constraints, and it is evaluating a bulk sale of crude held in inventory. Shareholders face a mix of stronger sales and a disruption to cash flow that the company is still working to resolve.
Q3 2026 total revenue of $154.4 million, up 13% quarter over quarter; cash and cash equivalents of $38.0 million at quarter end
Crude oil sales halted by sole downstream purchaser in early October 2026 for storage tank maintenance; sales to three additional Los Angeles-area refineries began in early November 2026
Platform Hondo final MMA inspections and initial production scheduled for November 2026, with all producing wells forecast online in December 2026 at about 10,000 gross barrels of oil per day
Sold 16,110,711 shares under its at-the-market program in Q3 2026 at an average of about $4.75 per share; no ATM sales in Q4 2026 to date
Kodiak Gas Services reported third quarter 2026 net income attributable to common shareholders of $71.5 million, or $0.70 per diluted share, compared with a net loss of $14.0 million a year earlier. The company also raised its full-year 2026 adjusted EBITDA and discretionary cash flow guidance, reflecting higher revenue and the DPS acquisition, which closed April 1, 2026.
Total revenues were $401.8 million, up from $322.7 million in the third quarter of 2025.
Net income attributable to common shareholders was $71.5 million, or $0.70 per diluted share, versus a loss of $14.0 million, or $0.17 per share, a year earlier.
Full-year 2026 adjusted EBITDA guidance was raised to $840 million to $860 million; discretionary cash flow guidance rose to $580 million to $600 million.
The quarterly dividend was $0.51 per share, and the share repurchase program was extended to December 31, 2027, with about $31.7 million available.
National Energy Services Reunited (NESR) reported third-quarter 2026 results with revenue of $504.7 million, up 70.9% from a year earlier, and net income of $34.3 million, up 93.5%. Both figures were lower than the June 2026 quarter, which the company attributed to changing activity levels in its hydraulic fracturing, well testing and wireline logging services. The board also declared a quarterly cash dividend of $0.10 per share.
Revenue was $504.7 million, up 70.9% year-over-year but down 3.1% from $520.8 million in the June 30, 2026 quarter.
Diluted EPS was $0.33, compared with $0.18 a year earlier and $0.43 in the June quarter.
Adjusted EBITDA was $95.9 million, up 49.9% year-over-year.
The board declared a $0.10 per share cash dividend payable December 10, 2026, to holders of record on December 3, 2026.
Berkshire Hathaway reported third-quarter 2026 net earnings of $22.1 billion, down from $30.8 billion a year earlier, as investment gains fell to $9.4 billion from $17.3 billion. For the first nine months, net earnings rose to $57.9 billion from $47.8 billion, and operating earnings rose to $37.0 billion from $34.3 billion, so the quarterly decline and the year-to-date gain point in different directions for shareholders.
Q3 2026 net earnings were $22.1 billion versus $30.8 billion in Q3 2025; Q3 operating earnings were $12.7 billion versus $13.5 billion.
First nine months 2026 net earnings were $57.9 billion versus $47.8 billion in the same period of 2025; operating earnings were $37.0 billion versus $34.3 billion.
Berkshire acquired about $9.6 billion of treasury shares in Q3 2026 and about $14.4 billion in the first nine months.
The results were released November 7, 2026 and furnished as Exhibit 99.1 to a Form 8-K dated November 9, 2026.
QXO said preliminary, unaudited third quarter 2026 net sales were approximately $4.90 billion, up 79% from $2.73 billion a year earlier, and adjusted EBITDA was approximately $557 million, up 85% from $301 million. GAAP net loss was approximately $123 million, compared with $139 million in the third quarter of 2025, and the company said the figures may change before it reports full results on November 12, 2026.
Net sales: approximately $4.90 billion, up 79% from $2.73 billion in Q3 2025
GAAP net loss: approximately $123 million, versus $139 million a year earlier
Adjusted EBITDA (non-GAAP): approximately $557 million, up 85% from $301 million; margin 11.4% versus 11.1%
Results include Kodiak Building Partners from April 1, 2026 and TopBuild Corp. from July 1, 2026; full results due November 12, 2026
EVgo reported third quarter 2026 results, with total revenue down 1% year-over-year while charging network revenue rose 29%. The net loss widened to $49.2 million, and the company updated its full-year 2026 guidance. The board also received a non-binding, unsolicited proposal from LS Power to acquire the shares it does not own for $2.00 per share in cash, which could affect shareholders if pursued.
Total Q3 2026 revenue was $91.4 million, down 1% from $92.3 million, while charging network revenue rose 29% to $71.8 million.
Q3 2026 net loss was $49.2 million, compared with $28.4 million in Q3 2025; adjusted EBITDA loss narrowed to $3.5 million from $5.0 million.
Updated 2026 guidance: total revenue of $375 million to $400 million and adjusted EBITDA loss of $15 million to $30 million.
On November 2, LS Power Equity Advisors proposed to acquire EVgo's Class A shares not already owned by LS Power for $2.00 per share in cash; a special committee of independent directors is reviewing it.
TEN Holdings reported third-quarter 2026 revenue of $640,000, up 17.9% from a year earlier, but its net loss rose 87.9% to $3,734,000. The loss reflects a $1.8 million write-off of previously capitalized service contracts and about $0.5 million in legal expenses, which the company calls non-recurring. Shareholders also face a change in finance leadership, as Ian M. Lawson became interim chief financial officer effective September 30, 2026.
Revenue was $640,000 versus $543,000 a year earlier; gross margin fell to 59.2% from 74.6%.
Net loss was $3,734,000, or $(0.31) per share, compared with $1,987,000, or $(0.84) per share, in the third quarter of 2025.
The company cited a $1.8 million write-off of capitalized service contracts and about $0.5 million in legal expenses.
Ian M. Lawson was appointed interim chief financial officer, effective September 30, 2026.
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
Sidus Space's audit committee concluded that its audited 2024 and 2025 annual reports and its 2026 quarterly reports for March 31 and June 30 should no longer be relied upon. The company expects the restatements to increase net loss for 2024 and for the first half of 2026, decrease net loss for 2025, and reduce stockholders' equity in every affected period, and it expects to report material weaknesses in internal controls.
Restatement covers the 2024 and 2025 annual reports and the Q1 and Q2 2026 quarterly reports; the 2024 and 2025 10-Ks were filed March 31, 2025 and April 1, 2026.
Net loss expected to increase by about $12.5 million for 2024 and about $4.1 million for the six months ended June 30, 2026; net loss expected to decrease by about $5.5 million for 2025.
Total stockholders' equity expected to decrease by about $15.0 million as of June 30, 2026, compared with amounts originally reported.
Main cause is warrant classification: 3,409,946 warrants issued December 17, 2024 should have been recorded as liabilities; the company also cited a $4.0 million impairment on its LS-2 satellite.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
Greif reported fourth-quarter and fiscal 2026 results for the year ended September 30, 2026. Full-year net income rose to $261.5 million, and Adjusted EBITDA rose 11.7%, while fourth-quarter Adjusted EBITDA fell 3.1% to $163.0 million and Adjusted free cash flow of $279.3 million was below the company's most recent guidance range. The company also gave fiscal 2027 low-end guidance of $645 million Adjusted EBITDA and $290 million Adjusted free cash flow.
Fiscal 2026 net income was $261.5 million, or $4.54 per diluted Class A share, versus $31.6 million, or $0.55, a year earlier.
Fourth-quarter net loss narrowed to $6.5 million, or $0.11 per diluted Class A share, from a net loss of $24.3 million, or $0.42, a year earlier.
Company will close its Sweetwater paperboard mill in Austell, GA, and has achieved $105 million in cumulative run-rate cost savings, with a new target of $150 million by the end of fiscal 2027.
Fiscal 2027 low-end guidance: Adjusted EBITDA of $645 million and Adjusted free cash flow of $290 million.
CPS Technologies reported fiscal third-quarter 2026 revenue of $8.9 million, up from $8.8 million a year earlier, with gross margin of 20.9% versus 17.1%. For the nine months, the company posted an operating loss of $423,415 compared with operating income of $542,659 a year earlier, and it signed a lease for an 80,000-square-foot facility in Attleboro, Massachusetts.
Q3 revenue of $8.9 million versus $8.8 million in the prior-year quarter
Q3 gross profit of $1.9 million, or 20.9% of revenue, versus 17.1% a year earlier
Q3 operating income of $357,747 versus $276,082; nine-month operating result was a loss of $423,415 versus income of $542,659
Company signed a long-term lease for an 80,000-square-foot facility in Attleboro, Massachusetts, about twice its current size
Hyster-Yale reported third-quarter 2026 revenue of $827 million, up from $813 million in the second quarter, and narrowed its operating loss to $9 million from $18 million. The company said it expects Q4 2026 revenue to grow sequentially on higher shipments, but tariff-related costs remain elevated and the company plans new cost-reduction programs targeting at least $100 million at maturity in 2029.
Q3 2026 revenue was $827 million versus $813 million in Q2 2026; net loss narrowed to $15 million from $32 million
Operating loss was $9 million in Q3 2026 versus an operating profit of $2.3 million in Q3 2025
Company expects Q4 2026 bookings to exceed Q4 2025 and Q3 2026, with sequential revenue growth
New programs targeting at least $100 million of cost reductions and mitigations at maturity, expected in 2029
BCP Investment Corporation postponed the release of its third quarter 2026 financial results and the related conference call, which were originally scheduled for November 5 and November 6, 2026. The company said the delay gives management more time to finalize financial disclosures, regulatory filings and structural terms tied to a potential strategic initiative, and that there is no assurance this will lead to a definitive agreement or transaction.
Q3 2026 results release and conference call postponed from November 5 and November 6, 2026
Delay tied to finalizing disclosures, regulatory filings and structural terms of a potential strategic initiative
Company states the delay is not related to any accounting, financial or regulatory matters
New call date and dial-in details to be issued by separate press release in the coming days
FB Bancorp reported third-quarter 2026 net income of $466 thousand, down from $1.1 million a year earlier, as non-interest expenses rose and net interest margin fell to 4.30% from 4.65%. Nine-month net income was $515 thousand versus $2.7 million, including a $1.1 million loss from discontinued mortgage banking operations. Shareholders face lower earnings and a commercial loan of approximately $19.8 million now classified as substandard.
Q3 2026 net income was $466 thousand versus $1.1 million in Q3 2025; continuing operations EPS was $0.03 versus $0.06.
Nine-month 2026 net income was $515 thousand, including a $1.1 million loss from discontinued operations, versus $2.7 million a year earlier.
Non-interest expenses rose $390 thousand, or 3.33%, in Q3 2026 year over year, with $686 thousand of stock-based compensation.
A commercial loan with a principal balance of approximately $19.8 million was classified substandard after two co-borrower entities filed for Chapter 11 in June 2026; no specific allowance was recorded.
Biglari Holdings reported third-quarter 2026 net earnings of $1.0 million, compared with a net loss of $5.3 million a year earlier. Pre-tax operating earnings rose to $9.9 million from $6.9 million, though the company said its investment gains and losses also affect reported results.
Q3 2026 pre-tax operating earnings were $9,874 thousand, up from $6,854 thousand in Q3 2025.
Nine-month 2026 net earnings were $26,409 thousand, up from $12,365 thousand in the same period of 2025.
Nine-month 2026 pre-tax operating earnings were $12,007 thousand, down from $20,521 thousand a year earlier.
Steak n Shake same-store sales rose 18.2% in Q3 2026 for domestic company-operated and franchise-partner-operated restaurants.
Star Holdings reported a third-quarter net loss attributable to common shareholders of $45.1 million, or $3.74 per share, for the quarter ended September 30, 2026. The loss reflects a non-cash mark-to-market adjustment of $53.1 million on its roughly 13.5 million Safehold (SAFE) shares, which reduced per-share earnings by $4.40. The company also raised cash through asset sales and cut its margin loan balance roughly in half, which matters to shareholders because the company says it plans to realize value mainly through asset sales and active asset management.
Q3 2026 net loss attributable to common shareholders: $45.1 million, or $3.74 per share
Non-cash SAFE adjustment of $53.1 million reduced earnings per share by $4.40
Sold municipal debt securities portfolio for $50.2 million, with a $4.5 million gain
Sold Coney Island land parcel for $20.0 million with a $4.7 million profit; margin loan reduced from $94.5 million to $46.5 million
Kestrel Group reported a third-quarter 2026 net loss of $16.4 million, or $2.09 per share, on total revenues of $4.8 million. Program Services fee income rose 203% year over year to $2.9 million, while the Legacy Reinsurance segment posted a $6.4 million underwriting loss. Management is targeting about $5 million in run-rate expense savings over the next year.
Q3 2026 net loss of $16.4 million, or $2.09 per share; total revenues of $4.8 million
Program Services fee income of $2.9 million, up 203% year over year; premium produced of $121.2 million, up 132%
Legacy Reinsurance segment underwriting loss of $6.4 million, including a $6.5 million loss in the Diversified business
Targeting approximately $5 million in run-rate expense savings over the next twelve months
DTE Energy Company furnished unaudited financial statements for its indirect subsidiary, DTE Gas Company, for the quarter ended September 30, 2026. DTE Gas reported a net loss of $29 million for the third quarter and net income of $176 million for the first nine months of 2026. These results provide transparency into the operating performance and financial condition of the utility subsidiary for shareholders.
DTE Gas reported operating revenues of $211 million for the third quarter ended September 30, 2026, compared to $207 million for the same period in 2025.
Net loss for the third quarter of 2026 was $29 million, improving from a net loss of $36 million in the third quarter of 2025.
For the nine months ended September 30, 2026, net income was $176 million, compared to $175 million for the first nine months of 2025.
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
Global Self Storage reported third-quarter 2026 results for the period ended September 30, 2026. Revenue rose 0.6% to $3.2 million and FFO and AFFO grew, but net income fell 16.0% to $417,000 and same-store occupancy slipped to 92.9% from 93.2% a year earlier. The company maintained its $0.0725 quarterly dividend and reported capital resources of about $24.3 million.
Total revenues rose 0.6% to $3.2 million; net income fell 16.0% to $417,000, or $0.04 per diluted share.
FFO rose 5.8% to $1.1 million ($0.09 per diluted share) and AFFO rose 4.7% to $1.1 million ($0.10 per diluted share); both are non-GAAP measures.
Same-store NOI fell 0.6% to $2.0 million, with cost of operations up 2.5% to $1.3 million.
Same-store occupancy was 92.9% as of September 30, 2026, versus 93.2% a year earlier; the quarterly dividend stayed at $0.0725 per share.
Ring Energy reported third-quarter 2026 results on November 5, 2026, with revenue down about 2% from the second quarter to $102.3 million, mainly on lower realized oil prices. The company posted a net loss of $16.6 million, or $0.06 per diluted share, compared with net income of $64.8 million in the prior quarter, which included a $41.0 million unrealized derivative loss this quarter, while adjusted net income rose 14% to $27.3 million.
Revenue $102.3 million, down about 2% from $104.7 million in Q2 2026; realized oil price $83.72 per barrel, down about 12%
Net loss $16.6 million ($0.06 per diluted share) versus net income $64.8 million in Q2 2026; includes a $41.0 million unrealized derivative loss
Adjusted net income $27.3 million ($0.10 per diluted share), up 14%; adjusted EBITDA $57.1 million, up 5%
Revolving credit facility borrowings reduced by $10.0 million to $350.0 million at September 30, 2026; Q4 2026 oil guidance 12,900 to 13,500 Bo/d
U.S. Physical Therapy reported third-quarter 2026 net revenue of $223 million, up 13% year over year, but posted a loss of $1.04 per share, compared with earnings of $0.48 per share a year earlier, mainly due to a non-cash contingent earn-out charge and noncontrolling interest effects described by the company. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million and declared a quarterly dividend of $0.46 per share.
Q3 2026 net revenue was $223 million, up 13% from Q3 2025; adjusted EBITDA was $28 million versus $24 million.
Q3 2026 loss per share was $1.04 versus earnings of $0.48 per share; adjusted earnings per share was $0.80 versus $0.66.
Full-year 2026 adjusted EBITDA guidance of $102 million to $106 million was reaffirmed.
Quarterly dividend of $0.46 is payable December 11, 2026, to holders of record on November 16, 2026.
NI Holdings reported third-quarter 2026 net income of $5.5 million, or $0.27 per basic share, compared with a net loss of $1.7 million, or $(0.08) per share, a year earlier. The improvement came mainly from a lower combined ratio, but gross premiums written fell 7.2% as the company continues to exit the Non-Standard Auto segment, which matters to shareholders because premium volume is shrinking.
Net income was $5.5 million for the quarter versus a $1.7 million loss in Q3 2025; nine-month net income was $18.2 million versus a $7.3 million loss.
Combined ratio improved to 93.6% from 109.1%, driven mainly by favorable prior-year loss reserve development in Non-Standard Auto.
Gross premiums written fell 7.2% to $54.3 million and net premiums earned fell 8.6% to $65.8 million; Non-Standard Auto premiums declined 100.2%.
Net investment income was $2.7 million, down 10.7%, as maturities and sales funded operating cash needs in Non-Standard Auto.
Hawaiian Electric Industries reported third quarter 2026 GAAP net income of $35 million, or $0.20 per diluted share, up from $31 million, or $0.18, a year earlier. Non-GAAP Core net income fell to $23 million, or $0.13 per share, from $33 million, or $0.19, as the company absorbed $14 million of storm costs and a $51 million Pacific Current impairment, offset in GAAP results by gains tied to its American Savings Bank stake.
Total third quarter revenues were $1.01 billion, compared with $791 million in the third quarter of 2025.
GAAP diluted EPS was $0.20 versus $0.18; Core diluted EPS was $0.13 versus $0.19.
The quarter included $64 million of pre-tax gains related to HEI's American Savings Bank investment and a non-cash $51 million pre-tax asset impairment at Pacific Current.
Hawaiian Electric recorded $14 million of incremental pre-tax storm costs for August and September, and its Core net income was $28 million versus $40 million a year earlier.
Gogo reported third quarter 2026 revenue of $213.2 million, down 5% from a year earlier, and a net loss of $3.2 million, compared with a $1.9 million loss in the same period of 2025. The company reiterated its 2026 guidance and said it amended and extended its roughly $600 million Term Loan B to October 2030, with $75 million in principal repayments committed through 2027.
Total revenue of $213.2 million, down 5% year over year; Military/Government service revenue rose 36% to $37.2 million
Net loss of $3.2 million (diluted loss of $0.02 per share) versus a $1.9 million loss in Q3 2025; Adjusted EBITDA of $41.0 million, down 27%
2026 guidance reiterated: total revenue of $870 million to $895 million and Adjusted EBITDA of $175 million to $185 million
Term Loan B extended to October 2030, with $30 million to be repaid by December 31, 2026 and $20 million more by December 31, 2027
BOK Financial furnished a November 2026 investor presentation summarizing its third-quarter 2026 results. Net income was $159.9 million, or $2.64 per diluted share, down from $176.5 million, or $2.92, in the second quarter but up from $140.9 million, or $2.22, a year earlier. The presentation also shows the 2026 full-year outlook as of October 20, 2026, which shareholders can compare with the company's prior guidance.
Q3 2026 net income was $159.9 million, or $2.64 per diluted share, versus $176.5 million, or $2.92, in Q2 2026 and $140.9 million, or $2.22, in Q3 2025.
Q2 2026 results included a net gain from the exchange of Visa B shares and a loss from repositioning the available-for-sale securities portfolio; excluding these, Q2 net income would have been $156.5 million, or $2.59 per diluted share.
Net interest margin rose 9 basis points to 3.00%, and period-end loans grew $646 million, or 2.4%, to $27.7 billion.
The 2026 outlook as of October 20, 2026 shows net interest income of $1.43 billion to $1.44 billion and a provision expense below $10 million.
York Water reported third quarter 2026 operating revenues of $24,333,000, up $3,972,000 from a year earlier, and net income of $7,809,000, up $1,608,000. Nine-month revenues rose to $67,922,000 and net income to $20,238,000, both higher than in the same period of 2025, mainly due to rate increases effective March 1, 2026. Both headline measures improved, which points to stronger results for shareholders.
Q3 2026 operating revenues $24,333,000 vs. $20,361,000 in Q3 2025; net income $7,809,000 vs. $6,201,000
Q3 2026 basic and diluted EPS $0.48, up from $0.43 a year earlier
Company estimates an additional $11.8 million of 2026 investment, excluding acquisitions
OneMedNet said it expects preliminary third-quarter 2026 revenue of about $1 million, up 242% from the prior quarter and 465% from the year-earlier quarter. It also guided to fourth-quarter 2026 revenue of $12 million to $14 million, pending customer acceptance of delivered data by quarter-end. The third-quarter figures remain preliminary and may change before the Form 10-Q, expected by November 16, 2026.
Preliminary Q3 2026 revenue of about $1 million for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from Q3 2025.
Q4 2026 revenue guidance of about $12 million to $14 million, pending customer acceptance of delivered data by quarter-end.
Q3 results are preliminary and subject to adjustment; the Form 10-Q is expected by November 16, 2026.
National HealthCare Corporation reported third-quarter 2026 net operating revenues of $407,971,000, up 6.6%, and adjusted net income of $28,154,000, up 13.8%. GAAP net income attributable to NHC fell to $13,637,000 from $39,239,000, and the company tied the adjusted gain mainly to 2026 facility acquisitions.
Net operating revenues were $407,971,000 for the quarter ended September 30, 2026, versus $382,661,000 a year earlier.
GAAP diluted EPS was $0.85 versus $2.50; adjusted diluted EPS was $1.76 versus $1.58.
Adjusted net income rose to $28,154,000 from $24,744,000, driven by the June 1, 2026 acquisition of five skilled nursing facilities and the July 1, 2026 acquisition of real estate from National Health Investors.
The GAAP decline reflects a $17,599,000 unrealized loss on marketable equity securities in the quarter, which the company excludes from adjusted results.
Minerva Neurosciences reported GAAP net income of $100.7 million for the quarter ended September 30, 2026, compared with a net loss of $2.7 million a year earlier. The company said the result was driven by a $109.6 million non-cash gain from changes in the fair value of its warrant liability, and excluding that gain and stock-based compensation, its adjusted net loss widened to $5.6 million from $2.5 million. For shareholders, the operating loss grew as research and development and general and administrative spending rose, and cash and equivalents fell to about $77.0 million.
GAAP net income of $100.7 million, or $1.94 per basic share and $(0.19) per diluted share, for the three months ended September 30, 2026, versus a net loss of $2.7 million a year earlier.
Non-cash warrant liability gain of $109.6 million; adjusted net loss was $5.6 million versus $2.5 million in the prior-year quarter.
R&D expense was $5.2 million versus $0.9 million, and G&A expense was $4.3 million versus $1.9 million.
Cash, cash equivalents, marketable securities and restricted cash were about $77.0 million at September 30, 2026, down from $82.4 million at December 31, 2025.
Immunocore reported third-quarter 2026 KIMMTRAK net revenue of $102.2 million, down from $103.7 million a year earlier, and a net loss of $14.2 million ($0.28 per share) versus a $0.2 million loss in Q3 2025. The company attributed the revenue decline mainly to U.S. wholesaler stocking in Q2 2026 and one extra week of U.S. sales in Q3 2025, and said underlying growth was about 10%. Nine-month revenue rose to $324.8 million from $295.5 million, and the nine-month net loss narrowed to $2.1 million from $5.5 million.
Q3 2026 net revenue was $102.2 million, versus $103.7 million in Q3 2025; the company cited about 10% underlying growth after adjusting for U.S. items
Q3 2026 net loss was $14.2 million ($0.28 per share), compared with $0.2 million ($0.00 per share) a year earlier
Nine-month 2026 revenue was $324.8 million, up from $295.5 million; nine-month net loss was $2.1 million ($0.04 per share)
Cash, cash equivalents and marketable securities were $901.3 million at September 30, 2026; the company expects about $120 million in sales-related rebate payments in Q4 2026
United Bancorp (UBCP) reported third-quarter 2026 net income of $1.4 million, or $0.25 per diluted share, down 27.4% from $1.9 million, or $0.34, a year earlier. Management attributed the decline to a $2,953,000 charge-off of a single commercial credit, which raised the quarter's provision for credit losses to $2,421,000. Total revenue rose 15.16% and pre-provision net revenue rose 66.45%, but the one-time loan loss reduced earnings for shareholders.
Q3 2026 net income of $1,401,000 and diluted EPS of $0.25, versus $0.34 in Q3 2025
Nine-month net income of $5,407,000 and diluted EPS of $0.94, versus $0.99 a year earlier
Single commercial borrower charge-off of $2,953,000 drove a Q3 provision for credit losses of $2,421,000
Non-GAAP pre-provision net revenue of $3,490,000 for Q3, up $1,393,000 year over year, including a $560,000 securities gain
Plains reported third-quarter 2026 results on November 6, 2026. Net income attributable to PAA fell to $363 million from $441 million, and diluted net income per common unit turned to a loss of $0.06 from a profit of $0.55, while adjusted EBITDA attributable to PAA rose 6% to $711 million on revenues of $15.2 billion. Management said the company is on track to meet full-year 2026 adjusted EBITDA guidance attributable to PAA of $2.880 billion, plus or minus $50 million, so unitholders see a mixed quarter: the operating measure grew, but reported profit declined.
Net income attributable to PAA was $363 million, down 18% from $441 million a year earlier.
Diluted net loss per common unit was $0.06, compared with earnings of $0.55 per unit in the third quarter of 2025.
Adjusted EBITDA attributable to PAA rose 6% to $711 million; revenues were $15.2 billion versus $11.6 billion.
Full-year 2026 adjusted EBITDA guidance attributable to PAA of $2.880 billion plus or minus $50 million was reaffirmed as on track, and a quarterly distribution of $0.4175 per unit was paid.
Plains All American reported third-quarter 2026 results on November 6, 2026. Revenue and adjusted EBITDA attributable to PAA rose, but net income attributable to PAA fell 18% and the per-unit result turned to a loss of $(0.06), which the company tied in part to a $358 million impact from repurchasing Series A preferred units. Management said it is on track to meet full-year 2026 adjusted EBITDA guidance of $2.880 billion, plus or minus $50 million.
Net income attributable to PAA was $363 million versus $441 million a year earlier; diluted net income/(loss) per common unit was $(0.06) versus $0.55.
Revenues were $15.173 billion versus $11.578 billion, and adjusted EBITDA attributable to PAA was $711 million, up 6%.
Full-year 2026 adjusted EBITDA attributable to PAA guidance of $2.880 billion plus or minus $50 million was reaffirmed as on track.
Distribution declared was $0.4175 per unit, up 10% from $0.3800 a year earlier.
Franklin Templeton announced preliminary fourth quarter and full-year results for the period ended September 30, 2026, reporting a quarterly net income of $380.1 million, or $0.72 per diluted share, alongside $20.8 billion in long-term net inflows. Total assets under management reached $1.795 trillion, reflecting an 8% increase year-over-year.
Preliminary fourth quarter net income was $380.1 million, or $0.72 per diluted share, compared to $117.6 million, or $0.21 per diluted share, in the prior-year period.
Long-term net inflows were $20.8 billion for the quarter ended September 30, 2026, and $84.1 billion for the full fiscal year.
Total assets under management were $1.795 trillion as of September 30, 2026.
The company repurchased 2.5 million shares of its common stock for $86.1 million during the fourth quarter.
DarkHorse Technologies reported third-quarter 2026 revenue of $3.0 million, up from $2.6 million a year earlier, and a net loss of $5.8 million, wider than the $4.2 million loss in the third quarter of 2025 but narrower than the $13.8 million loss in the second quarter of 2026. The company says the revenue gain mainly reflects the Cathedra Bitcoin operations acquired June 1, 2026, and the results have limited comparability with the prior year.
Revenue was $3.0 million in Q3 2026, versus $2.5 million in Q2 2026 and $2.6 million in Q3 2025.
Net loss was $5.8 million, or $0.65 per share, versus $4.2 million, or $1.49 per share, in Q3 2025.
Cash and cash equivalents were $8.8 million at September 30, 2026, up from $2.8 million at June 30, 2026.
Contracted power roughly doubled to about 100 MW after a 50 MW contract with Hopkinsville Electric System signed September 30, 2026.
CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.
Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026
Tredegar reported a third-quarter 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, compared with net income of $7.1 million, or $0.20 per share, a year earlier. Management said results were not where it wants them to be, citing lower building and construction demand at Bonnell Aluminum and weaker Surface Protection demand at High Performance Films. The results are a sharp drop in profitability for shareholders, and the filing gives no updated full-year guidance.
Q3 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, vs. net income of $7.1 million, or $0.20 per share, in Q3 2025
Q3 2026 Consolidated EBITDA from ongoing operations of $4.1 million, vs. $18.1 million in Q3 2025
Aluminum Extrusions Q3 2026 EBITDA from ongoing operations of $2.5 million, vs. $16.8 million in Q3 2025; sales volume fell 11.6%
Net debt rose to $32.7 million at September 30, 2026, from $28.4 million at December 31, 2025
Global Partners LP reported third-quarter 2026 net income of $52.4 million, or $1.26 per diluted common unit, compared with $29.0 million, or $0.66 per unit, a year earlier, while sales rose to $6.7 billion from $4.7 billion. The company said stronger Wholesale results more than offset lower retail fuel volumes, and it declared a $0.7850 per unit distribution payable November 13, 2026. The filing also says the credit agreement was extended to October 16, 2031.
Diluted earnings per common unit were $1.26 versus $0.66; net income was $52.4 million versus $29.0 million.
Adjusted EBITDA was $122.9 million versus $98.8 million; distributable cash flow was $70.1 million versus $53.0 million.
Wholesale product margin rose to $111.4 million from $78.0 million, while GDSO product margin fell to $210.6 million from $218.9 million, and GDSO gasoline volume was 361.3 million gallons versus 390.8 million.
Distribution of $0.7850 per unit is payable November 13, 2026 to holders of record on November 9, 2026; the credit facility maturity was extended to October 16, 2031.
Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.
Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million
Calumet reported third-quarter 2026 results, with sales of $1.68 billion, up from $1.08 billion a year earlier. Net income fell to $273.3 million from $313.4 million, and basic earnings per share were $2.91 versus $3.61, after non-cash derivative and RINs-related charges. Adjusted EBITDA rose to $322.0 million from $69.6 million, and the company said it has retired about $265 million of debt since July.
Q3 2026 sales of $1.68 billion vs. $1.08 billion in Q3 2025; net income of $273.3 million vs. $313.4 million
Basic EPS of $2.91 vs. $3.61 a year earlier; net income attributable to common shareholders of $256.4 million
Adjusted EBITDA of $322.0 million vs. $69.6 million; Adjusted EBITDA with Tax Attributes of $347.2 million vs. $92.5 million
Non-cash items included a $113.8 million unrealized derivatives loss and $176.7 million of RINs-related items; $150 million of 2028 Notes were redeemed on October 25, 2026
Georgia Banking Company filed an investor presentation with its third-quarter 2026 results, its first full quarter of combined operations with Tandem Bancorp, which closed June 1, 2026. Net interest income rose 8.0% from the second quarter to $31.4 million, while noninterest income fell 13.8% to $2.8 million and net interest margin declined to 4.17%.
Diluted EPS of $0.57 and operating EPS of $0.74 for the quarter; ROTCE 9.70% and operating ROTCE 12.41%
Net interest income $31.4 million, up 8.0% from 2Q26; NIM down 14 basis points, which the company attributed to higher cost of refinanced subordinated debt
Noninterest income $2.8 million, down 13.8% from 2Q26, due to lower retail mortgage originations
CET1 ratio 10.59% at quarter end, up from 10.29% in 2Q26; management plans to use the presentation in investor meetings beginning November 9, 2026
Dauch reported third quarter 2026 results with sales of $2.91 billion, up from $1.51 billion a year earlier, mainly because of the Dowlais acquisition. The company swung to a net loss attributable to Dauch of $45.3 million, or $(0.19) per share, compared with net income of $9.2 million, or $0.07 per share, a year earlier. It raised its full-year sales outlook but lowered its full-year Adjusted EBITDA range, so the results and guidance point in different directions for shareholders.
Third quarter sales were $2.91 billion versus $1.51 billion in Q3 2025; the Dowlais acquisition was the primary driver of year-over-year changes.
Net loss attributable to Dauch was $45.3 million, or $(0.19) per share, versus net income of $9.2 million, or $0.07 per share, in Q3 2025.
Adjusted EBITDA was $358.5 million, or 12.3% of sales, versus $195.7 million, or 13.0% of sales, a year earlier.
Full-year 2026 Adjusted EBITDA outlook was lowered to $1.35–$1.375 billion from $1.36–$1.425 billion, while the sales outlook was raised to $10.8–$10.875 billion from $10.6–$10.8 billion.
Strive reported GAAP net income of $509.0 million for the quarter ended September 30, 2026, compared with losses in the comparable 2025 periods. The filing attributes the result to a $533.7 million net unrealized gain on digital assets, while total revenues were $2.7 million. Shareholders should note the gain is a fair value adjustment on bitcoin, not operating income.
GAAP net income was $509.0 million, or $5.24 per diluted share, for the three months ended September 30, 2026; non-GAAP adjusted net income attributable to common stockholders was $494.6 million, or $5.46 per diluted share.
Net unrealized gain on digital assets was $533.7 million; total operating expenses were $38.7 million.
Strive acquired 8,136 bitcoin in the third quarter and 15,124 bitcoin from October 1 through October 30, 2026.
On October 20, 2026, Strive completed an offering of 7,000,000 SATS shares for net proceeds of approximately $609.0 million; cash and cash equivalents were $490.4 million as of October 30, 2026.
Aligos Therapeutics reported third quarter 2026 results on November 6, 2026, with a net loss of $21.9 million, down from $31.5 million a year earlier, as revenue rose and research and development spending fell to $18.9 million. Cash, cash equivalents and investments of $31.1 million are expected to fund planned operations only into the first quarter of 2027.
Net loss for the three months ended September 30, 2026 was $21.9 million, or $(2.09) per share, versus $31.5 million, or $(3.04) per share, a year earlier.
Revenue from customers was $2.8 million, up from $0.7 million, and licensing revenue was $39 thousand, compared with none in the prior-year quarter.
Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, down from $77.8 million at December 31, 2025.
Topline data from the Phase 2 B-SUPREME study of pevifoscorvir sodium are expected in late Q3 2027.
PPL reported third-quarter 2026 GAAP earnings of $367 million, or $0.49 per share, compared with $318 million, or $0.43 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 ongoing earnings forecast to a range of $1.92 to $1.96 per share and increased its long-term annual EPS growth target to 7% to 9% through at least 2030, supported by a $25 billion capital investment plan.
Announced third-quarter 2026 reported GAAP earnings of $0.49 per share on net income of $367 million.
Achieved third-quarter ongoing EPS of $0.54 compared to $0.48 in 2025.
Increased long-term annual EPS growth target to 7% to 9% through at least 2030.
Announced a $25 billion capital plan for 2027 to 2030, driving average annual rate base growth of 10%.
TechTarget reported third-quarter 2026 revenue of $119.2 million, down 2.5% from a year earlier, and said it now expects full-year 2026 revenue to be modestly lower than 2025. Its net loss narrowed sharply from the prior year, which included large goodwill impairment charges, but Adjusted EBITDA fell and the company gave a full-year 2026 Adjusted EBITDA range of $80 million to $85 million.
Q3 2026 revenue was $119.2 million, versus $122.3 million in Q3 2025; nine-month revenue was $341.4 million, versus $346.1 million
Q3 2026 net loss was $18.2 million, versus $76.8 million in Q3 2025; Q3 Adjusted EBITDA was $18.6 million, versus $22.6 million
Full-year 2026 Adjusted EBITDA outlook is $80 million to $85 million, with full-year revenue expected to be modestly lower than 2025
Cash was $35.3 million at September 30, 2026, with $120.1 million drawn on a $250 million revolving credit facility
Under Armour reported revenue of $1.24 billion for the quarter ended September 30, 2026, down 7% from a year earlier, while its net loss narrowed to $425 thousand from $18.8 million. The company raised its fiscal 2027 GAAP operating income outlook to $99 million to $119 million, but cut its expected gross margin improvement, which shareholders should weigh against the lower sales.
Q2 net revenues were $1.24 billion, down 6.9% from $1.33 billion; North America fell 7% and international fell 7%.
Q2 GAAP operating income was $15 million, versus $17 million a year earlier; adjusted operating income was $25 million.
Fiscal 2027 GAAP operating income outlook was raised to $99 million to $119 million, from $96 million to $116 million.
Expected gross margin improvement was lowered to 170 to 220 basis points from 220 to 270, citing fuel, freight and foreign exchange costs.
MSG Rangers reported its first quarter results as a standalone company after its October 26, 2026 spin-off from MSG Knicks. Revenue rose 3% to $14.1 million, but the operating loss widened to $23.6 million and the net loss per share was $1.39, versus $0.89 a year earlier.
Revenues of $14.1 million for the quarter ended September 30, 2026, up $0.4 million, or 3%, from $13.7 million
Operating loss of $23.6 million, up $10.7 million from $12.8 million, driven mainly by higher SG&A and direct operating expenses
Net loss of $16.9 million, or $1.39 per share, compared with a net loss of $10.8 million, or $0.89 per share, a year earlier
Net cash used in operating activities was $71.2 million for the quarter, compared with $5.1 million a year earlier
Telephone and Data Systems reported third quarter 2026 total operating revenues of $306.7 million, down from $308.5 million a year earlier, and net income attributable to TDS common shareholders of $29.6 million from continuing operations, compared with $40.2 million. The company lowered TDS Telecom's 2026 revenue, Adjusted OIBDA and Adjusted EBITDA guidance, raised its capital expenditure estimate, and its board approved an incremental $250 million share repurchase authorization.
Q3 2026 diluted EPS from continuing operations was $0.26, versus $0.33 in Q3 2025; total operating revenues were $306.7 million versus $308.5 million.
TDS Telecom 2026 revenue guidance was cut to $990 million to $1,010 million from $1,000 million to $1,025 million; Adjusted OIBDA guidance was cut to $280 million to $300 million from $300 million to $320 million.
TDS Telecom capital expenditure guidance was raised to approximately $750 million from $625 million to $675 million.
The board approved an incremental $250 million share repurchase authorization; TDS repurchased about 6 million shares in the quarter at an average price of $36.65.
MSG Knickerbockers Corp. reported results for the fiscal first quarter ended September 30, 2026, which include the New York Rangers business it spun off on October 26, 2026. Revenues rose 15% to $45.5 million and operating loss narrowed to $25.5 million, but net loss widened to $31.1 million, or $1.29 per share, from $8.8 million, or $0.37 per share, a year earlier. For shareholders, the top-line and operating results improved while the bottom-line loss grew.
Revenues of $45.5 million, up $6.0 million, or 15%, from the prior-year quarter, led by $3.1 million higher league distributions and $2.6 million higher food, beverage and merchandise sales
Operating loss of $25.5 million, improved $2.0 million, or 7%; adjusted operating loss of $20.0 million, improved $0.8 million, or 4%
Net loss of $31.1 million, or $1.29 per share, versus a net loss of $8.8 million, or $0.37 per share, a year earlier
Cash and cash equivalents fell to $40.0 million at September 30, 2026, from $164.5 million at June 30, 2026, after $146.3 million of cash used in operating activities
Sunstone Hotel Investors reported third-quarter 2026 net income attributable to common stockholders of $38.7 million, or $0.21 per diluted share, compared with a net loss of $2.9 million, or $(0.02) per share, a year earlier. The company raised its full-year 2026 guidance, including adjusted FFO per diluted share of $1.00 to $1.03, up from $0.93 to $0.98, and the quarter included a $31.5 million gain on sale of assets. For shareholders, the results and higher outlook reflect stronger hotel demand and continued stock repurchases, which the company says were completed at a discount.
Third-quarter RevPAR rose 11.4% to $235.22; Total RevPAR rose 10.5% to $394.97.
Adjusted FFO per diluted share rose 17.6% to $0.20; Adjusted EBITDAre rose 8.8% to $54.5 million.
2026 guidance raised: net income attributable to common per diluted share now $0.46 to $0.49 (prior $0.37 to $0.42); RevPAR growth now 9.5% to 10.5% (prior 7.0% to 9.0%).
From the start of 2026 through November 5, 2026, the company repurchased $196.9 million of common and preferred stock, with $310.6 million remaining under its authorization.
Array Digital Infrastructure reported third quarter 2026 results, with total operating revenues from continuing operations rising to $53.9 million from $47.1 million a year earlier. Net income attributable to Array shareholders from continuing operations fell to $69.6 million, or $0.81 per diluted share, from $108.8 million, or $1.25 per share, and the company reaffirmed its 2026 guidance, which it left unchanged.
Total operating revenues from continuing operations were $53.9 million, up from $47.1 million in the third quarter of 2025.
Diluted EPS from continuing operations was $0.81, compared with $1.25 a year earlier.
2026 guidance is unchanged: total operating revenues of $205-$215 million, Adjusted OIBDA of $60-$75 million, Adjusted EBITDA of $220-$235 million, and capital expenditures of $25-$35 million.
TDS said on September 1, 2026 that it is no longer pursuing its non-binding proposal to acquire the Array shares it does not own.
Alpha Metallurgical Resources reported a third-quarter 2026 net loss of $9.3 million, or $0.73 per diluted share, down from a $12.3 million loss in the second quarter but up from $5.5 million a year earlier. The company also issued 2027 operational guidance and said it has committed 3.5 million tons of domestic 2027 sales at an average of $135.48 per ton.
Q3 2026 net loss of $9.3 million ($0.73 per share), versus $12.3 million ($0.96 per share) in Q2 2026 and $5.5 million ($0.42 per share) in Q3 2025
Adjusted EBITDA of $29.4 million, up from $25.6 million in Q2 2026 but down from $41.7 million in Q3 2025
2027 guidance: 14.3 million to 15.7 million total tons shipped and cost of coal sales of $104.00 to $110.00 per ton
Stacker reclaimer at Dominion Terminal Associates damaged in a June storm; replacement expected to take a lengthy time, with insurer discussions ongoing
Sylvamo reported a third-quarter 2026 net loss of $199 million, or $4.98 per diluted share, driven by a $284 million loss from discontinued operations, primarily a noncash impairment tied to its Europe business. Sales from continuing operations of $645 million and adjusted operating earnings of $53 million were both lower than a year earlier but higher than the second quarter. The company also said it entered a put option agreement with Midas Atlantic Partners for a binding offer to acquire its Europe business, which it says would leave Sylvamo more focused on Latin America and North America.
Net sales from continuing operations were $645 million, versus $662 million in Q3 2025 and $614 million in Q2 2026.
Net loss was $199 million ($4.98 per diluted share), including a $284 million loss from discontinued operations.
Adjusted operating earnings were $53 million ($1.33 per diluted share), versus $72 million ($1.79) a year earlier.
Put option agreement with Midas Atlantic Partners for a binding offer to acquire the Europe business; dividend of $0.45 per share was paid Oct. 16.
Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% from a year earlier, and a narrower GAAP loss from continuing operations of $0.3 million. It raised the low end of its 2026 total revenue guidance and its 2026 adjusted EBITDA margin guidance, but cut its Commercial Channel growth guidance. In October, the FDA said the Hyalofast application is not approvable, which removes a near-term regulatory path for that product.
Revenue was $30.6 million versus $27.8 million; Commercial Channel rose 17% to $14.0 million and OEM Channel rose 5% to $16.6 million.
GAAP loss from continuing operations was $0.3 million, or $0.02 per diluted share, versus $3.2 million a year earlier; adjusted EBITDA was $5.1 million versus $0.9 million.
2026 total revenue growth guidance is now 6% to 10%, up from 5% to 10%; Commercial Channel guidance was cut to 9% to 13% from 12% to 18%.
In October, the FDA informed Anika that the Hyalofast pre-market approval application is not approvable, primarily based on the clinical data submitted.
InTest reported third-quarter 2026 revenue of $35.1 million, up 34% from a year earlier but essentially flat sequentially, and net earnings of $1.9 million, or $0.15 per diluted share, versus a net loss a year earlier. Orders reached a record $49.4 million, lifting backlog to $59.7 million, and management guided fourth-quarter 2026 revenue to $34.0 million to $36.0 million.
Revenue of $35.1 million, up 33.7% year-over-year and down 0.7% from the second quarter of 2026
Net earnings of $1.9 million, or $0.15 per diluted share, versus a net loss of $0.9 million, or $(0.08), in the prior-year quarter
Orders of $49.4 million, up 31.3% year-over-year, led by Semi orders of $25.1 million; backlog of $59.7 million
Fourth-quarter 2026 outlook: revenue of $34.0 million to $36.0 million and gross margin of approximately 45%
Brookfield Asset Management reported third-quarter 2026 results for the period ended September 30, 2026. Fee-related earnings and distributable earnings each rose 15% from a year earlier, and the company raised $25 billion of capital during the quarter. The board also declared a quarterly dividend of $0.5025 per share.
Fee-related earnings were $864 million, or $0.54 per share, in the quarter, up from $754 million a year earlier.
Distributable earnings were $763 million, or $0.47 per share, in the quarter, up from $661 million a year earlier.
Net income was $3.0 billion in the quarter and $5.4 billion over twelve months, including a $2.0 billion non-cash gain on the Oaktree acquisition and consolidation.
Quarterly dividend of $0.5025 per share is payable December 31, 2026, to holders of record on November 30, 2026.
Ubiquiti reported results for the fiscal first quarter ended September 30, 2026, with revenue of $1,026.2 million, up 39.9% from a year earlier, and GAAP diluted EPS of $5.29, up from $3.43. The company also declared a $1.00 per share cash dividend, but warned that rising component costs and supply constraints could pressure gross margins and revenue.
Revenue of $1,026.2 million versus $733.8 million a year earlier; Enterprise Technology made up $941.3 million
GAAP net income of $320.5 million and GAAP diluted EPS of $5.29, versus $207.9 million and $3.43 a year earlier
Gross profit margin of 47.3%, up from 46.0% a year earlier, though the company cited higher component costs that may pressure margins
$1.00 per share cash dividend payable November 23, 2026, to shareholders of record on November 16, 2026
E.W. Scripps reported third-quarter 2026 revenue of $545 million, up 3.6% from a year earlier, and net income attributable to shareholders of $20.7 million, or 21 cents per share, compared with a loss of $49 million in the prior-year quarter. Political revenue of $82.6 million supported results, while Scripps Networks revenue fell 14%. For the nine months, the company reported a loss of $1.2 billion, including a $1.1 billion goodwill and intangible impairment, and it expects Local Media revenue to rise in the low-to-mid 40% range in the fourth quarter.
Q3 revenue $545 million, up $19 million or 3.6%; political revenue $82.6 million versus $5.5 million a year earlier
Q3 net income attributable to shareholders $20.7 million or 21 cents per share, including $18.8 million in restructuring costs
Nine-month loss attributable to shareholders $1.2 billion or $12.73 per share, including a $1.1 billion impairment for Scripps Networks
Cash of $83.4 million and total debt of $2.5 billion at Sept. 30; company plans to pay down at least $150 million of debt in Q4
Canopy Growth reported fiscal second-quarter 2027 results for the three months ended September 30, 2026, with consolidated net revenue up 22% to C$81.4 million, led by a 141% rise in international cannabis sales. Net loss increased by $35.7 million from the prior-year quarter because of $35.8 million of fair value charges on Canopy USA related assets, and gross margin fell to 29% from 33%. Shareholders get higher sales and a narrower adjusted EBITDA loss, but a larger reported net loss.
Consolidated net revenue was C$81.4 million, up 22%; Cannabis segment revenue was C$66.2 million, up 30%.
International markets cannabis revenue rose 141% to C$12.3 million from C$5.1 million, driven by Germany and Poland.
Net loss rose by $35.7 million, driven by $35.8 million of fair value charges on Canopy USA related assets.
Adjusted EBITDA loss was C$2.9 million, an improvement of C$0.2 million or 6%; Storz & Bickel revenue fell 4% to C$15.1 million.
Treace Medical reported third-quarter 2026 revenue of $48.3 million, down 4% from $50.2 million a year earlier, while its net loss narrowed to $12.6 million from $16.3 million. The company raised its full-year 2026 Adjusted EBITDA outlook to a loss of $1.0 million to $2.0 million, from a prior loss estimate of $3.0 million to $5.0 million, and narrowed its revenue range to $206 million to $210 million.
Q3 2026 revenue was $48.3 million, down 4% from $50.2 million in Q3 2025; the company said bunion kit sales volume excluding stocking distributors grew mid-single digits.
Q3 2026 net loss was $12.6 million, or $(0.19) per share, versus $16.3 million, or $(0.26) per share, a year earlier.
Q3 2026 Adjusted EBITDA was $0.3 million, compared with a loss of $2.6 million in Q3 2025.
Full-year 2026 revenue guidance is $206 million to $210 million, versus the prior $204 million to $212 million; cash usage reduction of about 50% was reiterated.
Fluor Corporation announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $3.7 billion and GAAP net earnings of $158 million. The company achieved record quarterly new awards of $10.9 billion, lifting backlog to $34.3 billion, and affirmed its full-year 2026 adjusted EBITDA guidance of $500 million to $525 million.
Revenue reached $3.7 billion for Q3 2026, up 10% year over year.
New awards totaled a record $10.9 billion in the quarter, including $7.5 billion for LNG Canada Phase 2.
Backlog increased 21% year over year to $34.3 billion as of September 30, 2026.
Share repurchases totaled $300 million during the quarter and $1.1 billion year to date.
Essent Group Ltd. reported third quarter 2026 net income of $163.4 million, or $1.82 per diluted share, compared to $164.2 million, or $1.67 per diluted share, for the third quarter of 2025. The company declared a quarterly cash dividend of $0.35 per common share and announced a $500 million share repurchase authorization running through year-end 2028.
Net income for the quarter ended September 30, 2026 was $163.4 million, or $1.82 per diluted share.
Mortgage new insurance written for the third quarter of 2026 was $12.1 billion.
The Board declared a quarterly cash dividend of $0.35 per common share payable on December 10, 2026.
In November 2026, the Board approved a $500 million share repurchase authorization through year-end 2028.
TeraWulf reported third-quarter 2026 revenue of $76.2 million, up from $50.6 million a year earlier, with HPC lease revenue of $63.0 million. Net income attributable to the company was $709.9 million, driven mainly by a non-cash $728.4 million change in fair value of warrant and derivative liabilities, while operating loss widened to $88.2 million and non-GAAP Adjusted EBITDA was $(12.8) million.
Q3 revenue $76.2 million vs. $50.6 million a year earlier; HPC lease revenue $63.0 million
Net income attributable to TeraWulf $709.9 million, including a $728.4 million warrant fair value gain; operating loss $88.2 million vs. $24.7 million a year earlier
Adjusted EBITDA $(12.8) million vs. $18.1 million a year earlier; $2.4 billion cash, cash equivalents and restricted cash at quarter-end
Enbridge reported third-quarter 2026 GAAP earnings attributable to common shareholders of $1.3 billion, or $0.59 per share, up from $0.7 billion, or $0.30 per share, a year earlier, and adjusted earnings of $1.1 billion, or $0.49 per share, up from $0.46. The company reaffirmed its 2026 guidance and said CEO Greg Ebel will retire in January, with Michele Harradence to lead the company. All figures are in Canadian dollars.
Q3 GAAP earnings attributable to common shareholders of $1.3 billion ($0.59 per share) vs. $0.7 billion ($0.30) in Q3 2025; the increase was primarily due to non-cash, unrealized changes in the value of derivative financial instruments.
Q3 adjusted earnings of $1.1 billion ($0.49 per share) vs. $1.0 billion ($0.46) in Q3 2025; adjusted EBITDA of $4.4 billion vs. $4.3 billion.
2026 guidance reaffirmed: adjusted EBITDA of $20.2 billion to $20.8 billion and DCF per share of $5.70 to $6.10.
Greg Ebel is retiring in January; Michele Harradence will lead Enbridge.
Vistra Corp. reported third quarter 2026 net income of $1,140 million and ongoing operations adjusted EBITDA of $2,378 million, representing more than 50% growth year over year. The company raised and narrowed its full-year 2026 guidance, initiated 2027 guidance ranges, and authorized an additional $1.5 billion for share repurchases. Shareholders also saw the completed acquisition of Cogentrix Energy and the commencement of new solar operations.
GAAP third quarter 2026 Net Income reached $1,140 million, up from $652 million in the third quarter of 2025.
Ongoing Operations Adjusted EBITDA grew over 50% year over year to $2,378 million for the quarter.
Board of Directors authorized an additional $1.5 billion of share repurchases, expected to be used by year-end 2028.
2026 Ongoing Operations Adjusted EBITDA guidance range was narrowed and raised to $7.1 billion to $7.5 billion.
Charter Communications reported its third-quarter 2026 financial and operating results, highlighted by a pro forma net loss of $2.1 billion driven largely by a $6.3 billion franchise impairment charge. The company also announced a new operating model and a plan to achieve $2 billion in annualized operating expense savings over the next 18 months, alongside the recently completed Cox Communications acquisition.
Pro forma third quarter revenue declined 1.5% year-over-year to $16.5 billion, while actual revenue rose 9.1% to $14.9 billion following the Cox Transactions.
Pro forma net loss attributable to Charter shareholders reached $2.1 billion, primarily due to a $6.3 billion franchise impairment charge.
Charter announced a new plan targeting $2 billion in annualized run-rate operating expense savings over the next 18 months.
Spectrum Mobile added 508,000 pro forma lines in the third quarter, bringing total mobile lines to 13.5 million as of September 30, 2026.
Starwood Property Trust reported a third-quarter GAAP net loss of $389.7 million, alongside Distributable Earnings of $116.8 million, or $0.31 per diluted share. The company invested $3.2 billion during the quarter and repurchased $108 million of its common shares.
GAAP net loss of $389.7 million for the third quarter ended September 30, 2026, including a $336.6 million credit loss provision.
Distributable Earnings of $116.8 million, or $0.31 per diluted share.
Invested $3.2 billion in the quarter, bringing the commercial lending portfolio to a record $17.8 billion.
Repurchased $108 million of common shares and declared a dividend of $0.48 per share.
Moderna reported third-quarter 2026 revenue of $1.3 billion and net income of $0.2 billion, returning to a profit compared to a net loss in the same period last year. Driven by this performance and pipeline progress, the company raised its full-year 2026 revenue growth outlook to 15% to 25% and increased its expected year-end cash and investments balance to between $8.1 billion and $8.3 billion. Shareholders also received updates on positive Phase 3 data for intismeran in melanoma and the U.S. FDA approval of the mFLUSIVA vaccine.
Third-quarter 2026 total revenue grew 29% year-over-year to $1.3 billion, with GAAP net income of $162 million or $0.38 per diluted share.
Full-year 2026 expected revenue growth was raised to 15% to 25%, up from the previous expectation of up to 10% growth.
Year-end 2026 cash and investments are now projected to be $8.1 billion to $8.3 billion, bolstered by operational execution and a $2.6 billion net proceeds convertible notes offering.
Research and development expenses for 2026 are now expected to be approximately $2.7 billion, reduced from the prior estimate of approximately $2.9 billion.
JBG SMITH reported third-quarter 2026 results, with Core FFO attributable to common shares of $12.7 million, or $0.22 per diluted share, up from $9.1 million, or $0.15, a year earlier. The company also reported a net loss of $82.0 million, or $1.41 per share, compared with a $28.6 million loss a year earlier, and the loss included $69.2 million of impairment losses. For shareholders, core operating earnings improved, but the larger loss reflects write-downs on real estate.
Core FFO was $12.7 million, or $0.22 per diluted share, for the three months ended September 30, 2026, versus $9.1 million, or $0.15, a year earlier.
Net loss was $82.0 million, or $1.41 per diluted share, versus $28.6 million, or $0.48, in the prior-year quarter; impairment losses were $69.2 million.
Same Store NOI at the company's share rose 3.3% to $60.8 million, and the Same Store multifamily portfolio was 94.4% leased as of September 30, 2026.
The Board declared a quarterly dividend of $0.175 per common share, payable November 25, 2026, to holders of record as of November 12, 2026.
Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.
Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
Reported net income was $18 million, while adjusted EPS was $0.27.
Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.
Humana reported third-quarter 2026 financial results with GAAP earnings of $1.33 per share and an adjusted loss of $0.70 per share. The company raised its full-year 2026 adjusted EPS guidance to at least $9.50 while also expanding its CenterWell and Medicaid patient footprints.
Reported third-quarter 2026 GAAP EPS of $1.33 and an adjusted loss per share of $0.70.
Raised full-year 2026 adjusted EPS guidance to at least $9.50, up from the prior expectation of at least $9.00.
CenterWell Senior Primary Care grew by 146,800 patients year-to-date, representing a 30 percent increase.
Medicaid membership grew by 103,600 members, or 7 percent, year-to-date.
Marcus & Millichap reported third quarter 2026 revenue of $208.4 million, up 7.5% from a year earlier, and net income of $1.0 million, or $0.03 per diluted share, compared with $0.2 million, or $0.01, in the third quarter of 2025. The company said the results are preliminary until it files its Form 10-Q, and it expects near-term challenges in the commercial real estate market to extend through 2026.
Total revenue was $208.4 million versus $193.9 million; brokerage commissions rose 7.4% to $174.1 million, with Middle Market and Larger Transaction Market brokerage revenue up 18.1%.
Adjusted EBITDA was $8.2 million versus $6.9 million; cost of services rose to 64.0% of total revenue, up 160 basis points.
Nine-month revenue was $582.8 million, up 14.0%, and nine-month net income was $1.8 million, or $0.05 per diluted share, compared with a net loss of $15.2 million.
The company repurchased 912,957 shares for $23.9 million in the first nine months and had about $90.1 million remaining under its repurchase program as of November 3, 2026.
Ziff Davis reported unaudited third quarter 2026 results, with revenue down 5.6% from a year earlier and a swing to an operating loss of $33.6 million, including a $29.6 million goodwill impairment. Adjusted diluted EPS was $1.39 versus $1.40 a year earlier, and the company repurchased $92.0 million of its shares during the quarter. The company will discuss the results on a call on November 6, 2026.
Revenue was $289.3 million versus $306.5 million in Q3 2025; adjusted EBITDA was $82.2 million versus $97.8 million.
Net loss from continuing operations was $28.7 million, or $0.85 per diluted share, compared with a loss of $16.0 million, or $0.39 per share, in Q3 2025.
Adjusted diluted EPS was $1.39 compared with $1.40 a year earlier.
Share repurchases totaled $92.0 million in Q3 2026 and approximately $265 million for the first three quarters of 2026.
Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.
Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.
Avalanche Treasury Corp (AVAT) reported preliminary, unaudited third-quarter 2026 net income of approximately $54.6 million, or $1.53 per diluted share, with about $60 million from market-driven changes in the value of its AVAX holdings and realized losses. It also repurchased about 8% of its Class A shares at an average price of $1.14 and repaid its FalconX loan in full, and the full third-quarter results are due in November 2026.
Preliminary Q3 2026 net income of approximately $54.6 million, or $1.53 per diluted share; approximately $60 million of gains from market-driven changes in AVAX value and realized losses
Repurchased 2,889,440 Class A shares at an average of $1.14 per share, about $3.3 million in total, roughly 8% of Class A shares outstanding as of August 24, 2026
Held 13.31 million AVAX tokens as of September 30, 2026, with about 60% unlocked; about 91% was staked in September 2026
Conference call on November 19, 2026 at 4:00 p.m. ET to discuss third-quarter results
Mount Logan Capital reported third-quarter 2026 total revenues of $12.9 million, up 12% from $11.4 million a year earlier, and a net loss of $3.7 million versus $13.4 million in the third quarter of 2025. Basic loss per share was $0.33, compared with $1.64, and the company attributed the narrower loss mainly to transaction expenses from the prior-year TURN merger that did not recur. Segment Income fell to $3.2 million in the quarter, but year-to-date Segment Income rose 21% to $11.5 million.
Total revenues $12.9 million for Q3 2026, up 12% from $11.4 million in Q3 2025
Net loss $3.7 million, compared with $13.4 million in Q3 2025; basic loss per share $0.33 versus $1.64
Q3 Segment Income $3.2 million versus $4.2 million; year-to-date Segment Income $11.5 million, up 21%
Quarterly distribution of $0.03 per share payable November 30, 2026 to holders of record on November 19, 2026
Comstock reported third-quarter 2026 revenue of $17.9 million, up 34% from a year earlier, and net income of $0.6 million, up 9%. Adjusted EBITDA more than doubled to $2.3 million, although the quarter included a $1.0 million unrealized loss on its Jericho Energy Ventures equity investments. Headline revenue and profit measures improved for both the quarter and the first nine months, but the quarter's net income absorbed that investment loss.
Q3 2026 revenue was $17.9 million versus $13.3 million in Q3 2025; Adjusted EBITDA was $2.3 million versus $1.1 million.
Q3 diluted EPS was $0.06 versus $0.05; year-to-date diluted EPS was $1.05 versus $0.34, with year-to-date net income of $11.4 million.
Q3 net income includes a $1.0 million unrealized loss on Jericho (JEV) equity investments, which partially reverses a significant Q2 gain; the year-to-date gain remains up $3.7 million.
Managed portfolio grew to 115 assets, up from 91 a year earlier, including 12 new ParkX contracts in Q3.
Regency Centers reported third quarter 2026 net income attributable to common shareholders of $75.1 million, or $0.41 per diluted share, alongside Nareit FFO of $1.23 per diluted share. The company raised its full-year 2026 Core Operating Earnings guidance midpoint and increased its quarterly common stock dividend by 6% to $0.800 per share. Shareholders experienced higher year-over-year Same Property NOI growth and strong leasing spreads during the quarter.
Reported Q3 2026 Net Income Attributable to Common Shareholders of $75.1 million, or $0.41 per diluted share.
Raised full year 2026 Core Operating Earnings guidance range to $4.65 to $4.67 per diluted share.
Increased quarterly common stock cash dividend by 6% to $0.800 per share.
Same Property NOI increased year-over-year by 5.1% for the third quarter of 2026.
Tianci International reported fiscal 2026 results for the year ended July 31, 2026, in Exhibit 99.1 to this 8-K. Total revenue rose to $14,242,611 from $9,282,997, helped by $4,409,563 in first-year mineral sales, and the net loss narrowed to $2,454,798 from $2,686,357. Logistics revenue fell 0.7% and its gross profit percentage dropped to 2.29%, so the core business weakened even as total results improved.
Total revenue of $14,242,611 for the year ended July 31, 2026, versus $9,282,997 a year earlier.
Mineral sales, a new business, contributed $4,409,563 at a 7.43% gross profit percentage.
Net loss of $2,454,798 versus $2,686,357 in fiscal 2025; operations used $2,199,382 in cash.
A public offering completed in June 2026 produced net proceeds of $4,390,512.
Brighthouse Financial reported third quarter 2026 net income available to shareholders of $302 million, or $5.21 per diluted share, down from $453 million, or $7.89 per share, a year earlier. Adjusted earnings fell to $527 million, or $9.12 per share, from $970 million, or $16.87 per share, though the company said its annual actuarial review added $314 million of net favorable notable items. The company also said regulatory approvals for the pending $70.00 per share Aquarian Capital acquisition are not expected before the December 6, 2026 Outside Date, and the parties are discussing an extension.
Net income available to shareholders was $302 million, or $5.21 per diluted share, versus $453 million, or $7.89 per share, in the third quarter of 2025.
Adjusted earnings, less notable items, were $213 million, or $3.68 per diluted share, versus $261 million, or $4.54 per share, a year earlier.
Annuity sales were $2.4 billion, including $2.1 billion of Shield Level Annuities, with annuity sales down 12% quarter-over-quarter.
The merger agreement's Outside Date is December 6, 2026; the company and Aquarian Capital are discussing an extension, with no assurance of agreement.
LCI Industries reported third-quarter 2026 results on a call furnished in an 8-K. Net sales were just under $1 billion, down 4% from a year earlier, while adjusted diluted EPS rose to $2.21 from $1.97 and GAAP diluted EPS was $2.05. The company narrowed its full-year adjusted EPS outlook to $8.25 to $8.50 and said the proposed merger with Patrick Industries remains pending.
Q3 2026 net sales were just under $1 billion, down 4% year over year, mainly due to lower North American RV wholesale shipments.
Adjusted diluted EPS was $2.21 versus $1.97 a year earlier; GAAP net income was $50 million, or $2.05 per diluted share.
Full-year 2026 adjusted EPS range was tightened to $8.25 to $8.50; adjusted revenue is expected at $3.9 billion to $4 billion.
The company said it declined a Monomoy Capital proposal because its board judged it not superior to the proposed merger with Patrick Industries.
Tucows reported third-quarter 2026 revenue of $100.0 million, up 1.4% from a year earlier, and a net loss of $10.3 million, down from $23.0 million in the third quarter of 2025. Gross profit and Adjusted EBITDA rose, but the company said gross profit was driven mainly by a large, non-recurring rate adjustment from renegotiating its mobile contract, and cash and restricted cash fell to $41.0 million from $60.2 million at the end of the second quarter.
Revenue of $100.0 million, up 1.4% year over year, driven by revenue growth at Ting.
Net loss of $10.3 million, or $(0.92) per share, versus a net loss of $23.0 million, or $(2.08) per share, in Q3 2025.
Adjusted EBITDA of $18.6 million, up 39.8% year over year, mainly due to the mobile contract re-rate in the Corporate segment.
Cash and restricted cash of $41.0 million at September 30, 2026, down from $60.2 million at June 30, 2026.
Ready Capital reported a third-quarter 2026 GAAP net loss of $62.2 million, or $(0.40) per share, compared with a net loss of $16.7 million, or $(0.13) per share, a year earlier. Distributable loss was $(0.53) per share, and the company declared $0.01 per common share in dividends, down from $0.125 a year earlier, which matters to shareholders because it reflects weaker earnings and a much smaller dividend.
Q3 2026 GAAP loss per common share of $(0.40), versus $(0.13) in Q3 2025; nine-month loss per share of $(2.27)
Distributable loss per common share of $(0.53); before realized losses, $(0.21)
Dividends declared per common share of $0.01 in Q3 2026, versus $0.125 in Q3 2025
Book value of $6.44 per common share as of September 30, 2026; cash of $157 million and total leverage of 2.8x
Diodes reported third quarter 2026 revenue of $532.6 million, up 35.8% from a year earlier, with GAAP net income of $43.7 million, or $0.95 per diluted share, versus $0.31 a year earlier. The company expects fourth quarter revenue of about $550 million, plus or minus 3%, and non-GAAP adjusted EPS of $1.35, plus or minus $0.10. The results are preliminary and unaudited and remain subject to revision until the Form 10-Q is filed.
Q3 2026 revenue $532.6 million, up 35.8% from $392.2 million in Q3 2025
GAAP EPS $0.95 per diluted share vs $0.31 in Q3 2025; non-GAAP EPS $1.18 vs $0.37
Q4 2026 outlook: revenue about $550 million (plus or minus 3%); non-GAAP EPS $1.35 (plus or minus $0.10)
Private placement of 0.00% Convertible Senior Notes due 2031 totaling $375 million
PLAYSTUDIOS reported third-quarter 2026 revenue of $48.9 million, down from $57.6 million a year earlier, and a net loss of $11.0 million, up from $9.1 million. The company discontinued two products, Tetris Block Party and The Win Zone, and recorded $6.7 million in non-cash impairment charges plus a $9.2 million goodwill impairment. It is not providing formal financial guidance, which leaves shareholders without a forward outlook.
Q3 2026 revenue was $48.9 million versus $57.6 million in Q3 2025; direct-to-consumer revenue rose 108% to $16.0 million.
Net loss was $11.0 million versus $9.1 million; Consolidated AEBITDA rose to $10.0 million from $7.2 million.
Goodwill impairment of $9.2 million and a $6.7 million non-cash impairment charge tied to the discontinued products.
No formal financial guidance was provided; restructuring annualized savings range was raised to $37.0 million to $39.0 million, with $44.6 million left on the share repurchase authorization.
VAALCO reported a third-quarter 2026 net loss of $39.8 million ($0.38 per diluted share), compared with net income of $42.4 million in the second quarter, mainly due to $34.7 million of unrealized hedging losses. Net revenue and Adjusted EBITDAX both rose from the second quarter, and the company gave fourth-quarter 2026 sales volume and capital spending guidance.
Q3 2026 net loss of $39.8 million ($0.38 per diluted share) versus Q2 2026 net income of $42.4 million
Net revenue of $147.0 million, up 9% from Q2 2026; Adjusted EBITDAX up 30% to $71.1 million
Q4 2026 guidance: NRI sales volumes of 20,800 to 22,600 BOPD and capital expenditures of $55 million to $75 million
Quarterly dividend of $0.0625 per share payable December 22, 2026; conference call November 6, 2026 at 8:00 a.m. Central Time
Strawberry Fields REIT reported third-quarter 2026 results that were pulled down by a $24.6 million foreign currency transaction loss tied to the retirement of Bond Series A, C and D. Net loss was $14.8 million and FFO was negative $3.6 million, compared with net income of $8.9 million and FFO of $20.7 million a year earlier. AFFO, which excludes that loss, rose to $18.8 million, or $0.34 per share, from $18.1 million, or $0.33 per share.
Q3 2026 net loss of $14.8 million vs. net income of $8.9 million in Q3 2025
Q3 2026 FFO of negative $3.6 million ($0.65 per share loss) vs. $20.7 million ($0.37 per share) a year earlier
Q3 2026 AFFO of $18.8 million ($0.34 per share), up from $18.1 million ($0.33 per share)
Subsequent to quarter end on November 1, 2026, the company agreed to buy a 99-bed skilled nursing facility in Angola, Indiana for $15 million
NeOnc reported third-quarter 2026 results, with its net loss falling to $4.4 million from $8.6 million in the year-earlier quarter and total operating expenses declining to $5.8 million from $6.9 million. Cash and cash equivalents rose to $6.2 million at September 30, 2026, helped by a September registered direct offering of approximately $15 million gross, and the company said it will present NEO100 and NEO212 data on November 13, 2026.
Net loss attributable to common stockholders was $7.3 million, or $(0.28) per share, versus $8.6 million, or $(0.45) per share, in Q3 2025; the figure includes $2.8 million of noncash deemed dividends.
Cash and cash equivalents were approximately $6.2 million at September 30, 2026, up from approximately $2.0 million at June 30, 2026.
R&D expenses were $1.3 million, compared with $0.7 million in Q3 2025, while G&A expenses fell to $0.6 million from $0.9 million.
Data from NEO100 and NEO212 will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology Annual Meeting in Philadelphia.
PodcastOne said it expects record first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year, for the six months ended September 30, 2026. Second-quarter revenue is expected to be $15.2 million with Adjusted EBITDA of $1.4 million. These figures are preliminary, unaudited and subject to change, and the company's board has formed a special committee to evaluate inbound strategic interest, which may or may not lead to a transaction.
Expected first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year
Expected second-quarter revenue of $15.2 million and Adjusted EBITDA of $1.4 million
Special committee of independent directors formed after inbound interest from multiple strategic parties, first announced October 28; company intends to retain a financial advisor
Figures are preliminary and unaudited, not reviewed by MGO; no GAAP net income reconciliation was provided
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.